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GENERAL  INTRODUCTION 
Home mechanical ventilation 
The start of home mechanical ventilation (HMV) was in fact the result of the polio epidemic in 
1950. During this epidemic patients needed ventilatory support and intensive care units had to 
be set up. As these patients needed ventilatory support sometimes continuously and no other 
medical need for staying in the hospital was present, HMV was started. While it took many 
years to start HMV in the Netherlands, the last decades we see an enormous growth in the 
number of patients on HMV. In 1991 there were 200 patients on HMV and this has increased 
to almost 3000 in 2015 [1]. The primary goal of HMV is to improve quality of life by reducing 
the signs and symptoms of chronic hypoventilation. Reduction of the carbon dioxide (pCO2) 
concentration in the blood, especially at night, is essential, and hypoxemia improves at the 
same time. Hypoventilation, by muscle weakness or reduced mobility of the thoracic cage, can 
cause a number of complaints such as; poor sleep quality, sudden awakenings with a panic 
sensation, headache upon awaking, spontaneous dyspnoea at night, concentration problems, 
drowsiness and decreased appetite. These complaints disappear after the start of HMV [2]. 
Home mechanical ventilation (HMV) is an effective treatment specifically in patients with a 
neuromuscular disease or a thoracic cage problem combined with daytime hypercapnia  [2-4]. 
Examples of these neuromuscular diseases include diaphragm paralysis, Duchene muscular 
dystrophy, myotonic dystrophy, limb girdle dystrophy, fascioscapulohumerale dystrophy, 
amyotrophic lateral sclerosis (ALS) and others. Examples of a restrictive disorders caused by a 
thoracic cage problem are kyphoscoliosis and obesity hypoventilation syndrome. HMV further 
developed due to a rapid technical progress in ventilators and wheelchair technology, 
improving patients’ mobility and participation in life, making the option of HMV more 
attractive. The change from invasive to non-invasive positive pressure ventilation starting in 
the 1980s also contributed to the 10% growth we see in the Netherlands every year  [1,5]. 
Currently, HMV is judged as an effective treatment as it can improve both survival and quality 
of life  [6-9]. 
Respiratory failure 
Respiratory failure is a condition in which the respiratory system fails to exchange carbon 
dioxide and oxygen. Pathophysiological, respiratory failure can be divided into two types. 
Hypoxemic respiratory failure, type I, is characterized by an arterial oxygen tension of < 8.0 
kPa with a normal carbon dioxide tension. Hypercapnic respiratory failure, type II, is 
characterized by an arterial carbon dioxide tension of > 6.0 kPa. Respiratory failure can occur 
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as acute, chronic or acute-on-chronic. HMV is the treatment of choice in case of hypercapnic 
respiratory failure. 
Hypercapnic respiratory failure in neuromuscular disease 
Patients with neuromuscular diseases comprise a heterogeneous group, which includes many 
uncommon diseases [10]. In this group of patients the ventilatory pump is no longer sufficient 
due to muscle weakness, leading to an increase in pCO2. Sometimes the patient is not aware of 
these symptoms as he or she gradually adjusts to this situation and does not feel impaired. 
Therefore, patients with a neuromuscular disease need to be monitored to detect symptoms of 
hypoventilation early, especially during the night, as hypoventilation will start first in this 
situation.  Monitoring can start also by assessing vital capacity (VC). If the VC drops below 
60% it should be followed with repetitive measurements of spirometry to evaluate the 
progression of the disease.  Hypoventilation is usually seen when VC < 40% of predicted and 
once VC drops < 25% at daytime, hypercapnic respiratory failure occurs [11]. Diaphragm 
paralysis caused by spinal cord injury, thoracic surgery or neuralgic amyotrophy is also part of 
this group. In case of unilateral diaphragm paralysis there is often no hypercapnic respiratory 
failure, but the orthopnoea can nevertheless be a reason to start HMV in these patients.   
Hypercapnic respiratory failure in restrictive thoracic disorders 
Various etiologies, causing deformities of the thoracic cage, lead to restrictive thoracic 
disorders, characterized by reduced thoracic cage compliance [12,13]. In patients with a 
restrictive thoracic cage disorder the respiratory muscles are at a mechanical disadvantage due 
to their suboptimal contraction length. This causes an ineffective interaction between the 
respiratory muscles and the thoracic cage, and increases the inspiratory muscles load leading to 
respiratory failure [14].  
Monitoring of respiratory failure 
Transcutaneous monitoring   
The measurement of oxygen and carbon dioxide is used to monitor the respiratory status of a 
patient. The “gold standard” is still the analysis of arterial blood samples, however, this an 
invasive procedure. In 1960 Severinghaus was the first to look for a non-invasive method to 
measure carbon dioxide on the human skin surface [15]. Non- invasive measurement of 
transcutaneous carbon dioxide by local heating of the skin tissue through a sensor, has been 
tested in several settings [16-19]. They all showed that transcutaneous monitoring can replace 
the arterial sampling of carbon dioxide with clinically acceptable accuracy in adults with 






Dutch regulations for HMV demand initiation of ventilatory support in the hospital. However, 
especially disabled patients with a personal tailored care system at home are frequently not 
satisfied with the level of care in the hospital. In these circumstances telemonitoring could be 
considered to monitor patients’ status at distance. In other diseases telemonitoring allows 
reduction of chronic disease complications, provides health care services without using hospital 
beds and reduces patient travel time, time off work and overall costs [20]. Telemonitoring at 
home in case of HMV would need transmittal of data of the mechanical ventilator and the 
transcutaneous monitor of oxygen saturation and carbon dioxide pressure. In this thesis the 
initiation of non-invasive ventilation outside the hospital by using telemonitoring is described.  
Treatment of respiratory failure 
Non-invasive ventilation 
Currently the most used form of HMV is non-invasive ventilation (NIV), which is mechanical 
ventilation administered via a nasal, mouth-nasal, full face mask or mouthpiece. The use of 
NIV has markedly increased over the past two decades and has now become an integral tool in 
the management of both acute and chronic respiratory failure, in both the home setting and in 
the hospital [21]. Invasive ventilation is only used in 15-20% of the HMV population in the 
Netherlands.  
Improvements in symptoms and daytime arterial blood gas tensions are consistently seen in 
patients with HMV [22] (table 1). There are three different theories how NIV might improve 
alveolar ventilation and gas exchange. The first is that the respiratory muscles rest during NIV  
[23,24]. The second theory is resetting the pCO2  [25] which means that ventilation will get 
more responsive to an increase in pCO2. Finally changes in the pulmonary mechanics after the 
start of NIV might result in an increased respiratory muscle strength and re-expansion of areas 
of atelectasis  [26]. A recent study in patients with a restrictive thoracic disorder showed that 
the increased ventilatory response to carbon dioxide after the initiation of NIV is probably the 









Table 1. Effects of chronic non-invasive positive pressure ventilation  [21].  
Short term effects Long-term effects 
Increased ventilation Improved exercise capacity 
Reduced work of breathing Improved sleep duration and quality 
Improved blood gasses Increased quality of life 
Increased strength and endurance of 
respiratory muscles 
Reduced hospitalization rates 
 Prolonged survival 
 
Diaphragm pacing stimulation 
Another more experimental therapy is diaphragm pacing primarily used in patients with a 
Spinal Cord Injury (SCI). In case of high cervical spinal cord injury this is mostly invasive for 
24 hours a day. Diaphragm pacing is a technique in which the diaphragm is stimulated by an 
external pacemaker [27]. By electrical stimulating the diaphragm the muscle contracts, moves 
down creating under pressure in the thoracic cage, and allowing air to be sucked into the lungs. 
After this inspiration, exhalation follows the moment there is no stimulus. Diaphragm pacing 
might by an attractive alternative as it can replace non-invasive or even invasive ventilatory 




Aims and outline of this thesis  
Ever since the 1950s when poliomyelitis patients were helped by chronic ventilatory support 
there has been a need for better techniques to transfer care from the hospital to the home 
environment. The overall topic of this thesis is innovation in the field of chronic ventilatory 
support with regard to both diagnosis and treatment.  
In chapter 2 we describe the situation of home mechanical ventilation in the Netherlands from 
the start until now. 
Chapter 3 shows the results of the validation of a transcutaneous carbon dioxide monitor 
compared to the golden standard being the assessment of carbon dioxide from arterial blood.  
In chapter 4 we present the results of our randomized controlled trial to investigate if initiation 
of chronic ventilatory support at home is as effective as initiation in the hospital (EOLUS). 
In chapter 5, a post hoc analysis on the EOLUS data focusing on differences in outcome 
between ALS and non-ALS patients is presented.  
In chapter 6 the reason for the institution of a data safety and monitoring board in the EOLUS 
study and advice for high risk, investigator initiated studies is discussed.  
Diaphragm pacing as an alternative for chronic ventilatory support is presented in chapter 7.  
Chapter 8 comments on the lack of efficacy of diaphragm pacing in patients with amyotrophic 
lateral sclerosis. We describe how spirometry assessed while the patient is in different positions 
can be helpful to evaluate diaphragmatic function in chapter 9 and when a drop in vital 





1.Vereniging Samenwerkingsverband Chronische Ademhalingsondersteuning.  
 http://www.vsca.nl/. January 2016.  
2. Meinesz AF, Bladder G, Goorhuis JF, Fock JM, Staal-Schreinemachers AL, Zijlstra JG, 
Wijkstra PJ. 18 years experience with mechanical ventilation in patients with Duchenne 
muscular dystrophy. Ned Tijdschr Geneeskd 2007; 151: 1830-1833. 
3. Meinesz AF, Wijkstra PJ, Zijlstra JG, Albers MJ, Koter GH. From the poliomyelitis 
epidemic to the founding of artificial respiration centres, intensive care units and centres for 
home mechanical ventilation. Ned Tijdschr Geneeskd 2006; 150: 444-449. 
4. Duiverman ML, Bladder G, Meinesz AF, Wijkstra PJ. Home mechanical ventilatory support 
in patients with restrictive ventilatory disorders: a 48-year experience. Respir Med 2006; 100: 
56-65.  
5. Make BJ. Epidemiology of Long-Term Ventilatory Assistance. In: Hill NS, ed. Long-Term 
Mechanical Ventilation. Dekker New York, 2000; pp. 1--17. 
6. Budweiser S, Hitzl AP, Jorres RA, Schmidbauer K, Heinemann F, Pfeifer M. Health-related 
quality of life and long-term prognosis in chronic hypercapnic respiratory failure: a prospective 
survival analysis. Respir Res 2007; 8: 92. 
7. Windisch W. Impact of home mechanical ventilation on health-related quality of life. Eur 
Respir J 2008; 32: 1328-1336. 
8. Domenech-Clar R, Nauffal-Manzur D, Perpina-Tordera M, Compte-Torrero L, Macian-
Gisbert V. Home mechanical ventilation for restrictive thoracic diseases: effects on patient 
quality-of-life and hospitalizations. Respir Med 2003; 97: 1320-1327. 
9. Leger P, Bedicam JM, Cornette A, Reybet-Degat O, Langevin B, Polu JM, Jeannin L, 
Robert D. Nasal intermittent positive pressure ventilation. Long-term follow-up in patients 
with severe chronic respiratory insufficiency. Chest 1994; 105: 100-105. 
10. Simonds AK. Assessment and Selection of Patients for Home Ventilation. In: Simonds AK, 
ed. Non-Invasive Respiratory Support: A Practical Handbook. London, Hoddor Arnold, 2007; 
pp. 155-176. 
11. Ragette R, Mellies U, Schwake C, Voit T, Teschler H. Patterns and predictors of sleep 
disordered breathing in primary myopathies. Thorax 2002; 57: 724-728. 
12. Bergofsky EH. Respiratory failure in disorders of the thoracic cage. Am Rev Respir Dis 
1979; 119: 643-669. 
13. Shneerson JM, Simonds AK. Noninvasive ventilation for chest wall and neuromuscular 




14. Nickol AH, Hart N, Hopkinson NS, Moxham J, Simonds A, Polkey MI. Mechanisms of 
improvement of respiratory failure in patients with restrictive thoracic disease treated with non-
invasive ventilation. Thorax 2005; 60: 754-760. 
15. SEVERINGHAUS JW. Methods of measurement of blood and gas carbon dioxide during 
anesthesia. Anesthesiology 1960; 21: 717-726. 
16. Storre JH, Steurer B, Kabitz HJ, Dreher M, Windisch W. Transcutaneous PCO2 monitoring 
during initiation of noninvasive ventilation. Chest 2007; 132: 1810-1816. 
17. Senn O, Clarenbach CF, Kaplan V, Maggiorini M, Bloch KE. Monitoring carbon dioxide 
tension and arterial oxygen saturation by a single earlobe sensor in patients with critical illness 
or sleep apnea. Chest 2005; 128: 1291-1296. 
18. Janssens JP, Perrin E, Bennani I, de MB, Titelion V, Picaud C. Is continuous 
transcutaneous monitoring of PCO2 (TcPCO2) over 8 h reliable in adults? Respir Med 2001; 
95: 331-335. 
19. Bendjelid K, Schutz N, Stotz M, Gerard I, Suter PM, Romand JA. Transcutaneous PCO2 
monitoring in critically ill adults: clinical evaluation of a new sensor. Crit Care Med 2005; 33: 
2203-2206. 
20. Meystre S. The current state of telemonitoring: a comment on the literature. Telemed J E 
Health 2005; 11: 63-69. 
21. Muir JF, Ambrosino N, Simonds AK. European Respiratory Monograph Non-invasive 
Ventilation Second Edition. European Respiratory Society Journals Ltd ©2008, Latimer Trend 
& Co. Ltd, Plymouth, UK, 2008. 
22. Simonds AK, Elliott MW. Outcome of domiciliary nasal intermittent positive pressure 
ventilation in restrictive and obstructive disorders. Thorax 1995; 50: 604-609. 
23. Roussos C. Function and fatique of respiratory muscles. Chest 1985; Aug;88(2 Suppl): 
124S-134S. 
24. Carrey Z, Gottfried SB, Levy RD. Ventilatory muscle support in respiratory failure with 
nasal positive pressure ventilation. Chest 1990; 97: 150-158. 
25. Goldstein RS, Molotiu N, Skrastins R, Long S, de Rosie J, Contreras M, Popkin J, 
Rutherford R, Phillipson EA. Reversal of sleep-induced hypoventilation and chronic 
respiratory failure by nocturnal negative pressure ventilation in patients with restrictive 
ventilatory impairment. Am Rev Respir Dis 1987; 135: 1049-1055. 
26. Hill NS. Noninvasive ventilation. Does it work, for whom, and how? Am Rev Respir Dis 
1993; 147: 1050-1055. 
27. Onders RP, Elmo M, Khansarinia S, Bowman B, Yee J, Road J, Bass B, Dunkin B, 
Ingvarsson PE, Oddsdottir M. Complete worldwide operative experience in laparoscopic 
diaphragm pacing: results and differences in spinal cord injured patients and amyotrophic 










Nederlands Tijdschrift voor Geneeskunde 2012; 156: A3609 
 




Anda Hazenberg  
Nicolle A.M. Cobben 
Mike J. Kampelmacher 
Jacqueline Rischen 





 The number of Dutch patients with home mechanical ventilation increased from 200 
to 2000 over the last 20 years. 
 
 Home mechanical ventilation is a cost effective treatment that significantly improves 
quality of life. 
 
 Eighty three percent of the patients with home mechanical ventilation lives at home. 
 
 An extra growth is to be expected of patients with obesity hypoventilation syndrome 
and a new potential group of patients with chronic obstructive pulmonary disease 
(COPD). 
 
 Strict regulations are necessary to ensure safety in the complex care that entails home 
mechanical ventilation. 




A patient with home mechanical ventilation is dependent on a mechanical ventilator, usually 
for the rest of their life. In the Netherlands home mechanical ventilation started in 1960. As a 
spin off after the poliomyelitis epidemic, in the 50’s, a large group of patients had become 
dependent on long-term mechanical ventilation [1]. In the 80's non-invasive positive pressure 
ventilation started (NPPV) [2,3]. This way of ventilatory support uses a mask over nose and or 
over mouth of the patient (figure 1). Correct ventilator settings ensure an increase in ventilation 






Choice of masks; a = full face mask; b = nasal mask   
 
The last 20 years the number of patients with home mechanical ventilation is registered by the 
4 centres of home mechanical ventilation (HMV), in Groningen, Maastricht, Rotterdam and 
Utrecht. In 1991 there were 200 of these patients in Netherlands, in 2011 this number increased 
to 2000. 
In this article we will provide more information about HMV because it is the expectation that 
more and more health care providers will be confronted with patients on HMV. The indications 
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and the results, especially the effect on quality of life, after starting with HMV will be 
highlighted. 
Aim of home mechanical ventilation 
The primary goal of HMV is to improve quality of life by reducing the signs and symptoms of 
chronic hypoventilation. Reduction of the carbon dioxide (pCO2) tension in the blood, 
especially at night, is essential, while hypoxemia (pO2 < 9.5 kPa) will improve as well. 
Hypoxemia alone is not an indication to start HMV. 
Hypoventilation, caused by muscle weakness or thoracic cage problems, causes a number of 
complaints like; general malaise, headache upon awakening, nightmares, spontaneous 
dyspnoea at night, concentration disorders, drowsiness and decreased appetite. Sometimes the 
patient is not aware of these symptoms as he or she has gradually adjusted to this situation and 
does not sense the impairment. 
Publications 
Various studies have shown that HMV is effective by improving quality of life, functional 
status and survival [4-9], normally by improving gas exchange. 
A recent study showed that after starting HMV in 85 patients, regardless of the underlying 
diagnosis, quality of life improved significantly [5]. In this study the Severe Respiratory 
Insufficiency (SRI) questionnaire was used. The SRI was developed to detect an improvement 
in quality of life in patients with chronic respiratory insufficiency. It showed a significant and 
clinically relevant improvement after 1 month of HMV; while after 1 year this improvement 
was still present. 
Another study showed that the social and mental functioning of patients improved after starting 
HMV and that they had an increased vitality and better cognition [6]. In patients with 
Duchenne muscular dystrophy the endurance capacity of the ventilatory muscles improved 
after starting with HMV [7].  
HMV also has a positive impact on survival, as shown in 2 Dutch studies. In patients with 
Duchenne muscular dystrophy, 5 years after starting HMV, 70% was still alive while 70% of 
the patients with post-poliomyelitis syndrome was still alive after 10 years [8,9]. In addition 
HMV not only reduced the number of hospitalizations, it was also cost effective [10]. Finally, 
the fact that in the Netherlands today 83% of patients with HMV lives at home, suggest that 
HMV has also a positive effect on the quality of life and physical functioning (figure 2) 
(www.vsca.nl). 
 






Place of residence of patients with home mechanical ventilation in the Netherlands 
Indications for HMV 
Patients eligible for HMV can be divided into 4 groups (figure 3). The first group includes 
patients with a neuromuscular, central or peripheral nervous system disorder. Examples are 
patients with muscular dystrophy (Duchenne muscular dystrophy, for example), amyotrophic 
lateral sclerosis (ALS), spinal cord injury or a diaphragm paralysis. 
The second group consists of patients with a thoracic cage problem, for example congenital 
kyphoscoliosis. The obesity hypoventilation syndrome also belongs in this group, as the 
obesity has a negative effect on the mobility of the thoracic cage. The latter diagnosis is valid if 
patients fulfil all following criteria; a BMI > 30 kg/m2, an arterial pCO2 > 6.0 kPa (45 mmHg) 
while the hypercapnia cannot be explained by another condition than the obesity. 
The third group entails patients with lung diseases. No consensus exists currently in the 
Netherlands regarding HMV in patients with chronic obstructive pulmonary disease (COPD). 
Patients who are on the waiting list for lung transplantation, for example patients with cystic 






































The fourth group are patients with sleep related breathing disorders, like obstructive sleep 
apnoea syndrome (OSAS) and central sleep apnoea syndrome (CSAS). If continuous positive 
airway pressure (CPAP) is not effective, HMV might be an option. 




Indication for home mechanical ventilation and numbers of patients over the last 20 years; NMD: neuromuscular 
disease; Thoracic: thoracic cage problem; Lung: lung diseases; OSAS: obstructive sleep apnoea syndrome; CSAS: 
central sleep apnoea syndrome. 
Initiation of HMV 
In 2010, the 4 HMV centres developed criteria to define when patients should be referred. This 
is published on the website of the Dutch organization; Vereniging Samenwerkingsverband 
Chronische Ademhalingsondersteuning (www.vsca.nl). Last year HMV in the Netherlands was 
initiated in 531 patients in the 4 centres either an intensive or- medium care unit or a ward with 
specific expertise. 
At this moment a study is performed in which patients with a neuromuscular disorder or a 
thoracic cage problem start HMV at home. In 51 of the 55 participants the initiation was 
successful (unpublished data). Another study resulted in a success rate of 85%, however this 
was in patients with COPD in a clinical setting [11]. The use of the optimal equipment and 
appropriate mask is crucial, it takes time and needs individual attention [5]. The centres of 
HMV have enough expertise to guide the patient professionally during the entire process of 
HMV. 
Home mechanical ventilation in the Netherlands 
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Experiences in different diagnoses 
Duchenne muscular dystrophy  
Nowadays non-invasive ventilatory support in patients with Duchenne muscular dystrophy is 
the most frequent application of HMV and therefore the number of patients that needs a 
tracheostomy over the last 10 years has decreased from 40% to 19%. In patients with HMV 
using a mask during the night and a mouthpiece during daytime, survival increased; HMV by 
mouthpiece is safe for most of these patients [12]. A recent Belgian study has shown that the 
workload of the respiratory muscles during the day can be reduced if patients were ventilated 
during the day by mouthpiece in combination with mask ventilation during the night [7].  
Patients with Duchenne muscular dystrophy using HMV experienced the possibility to lead an 
independent life. The quality of life increased from the start with HMV by improving sleep 
quality and reducing the complaints caused by hypoventilation. It was striking that the score 
for quality of life in these patients was similar in many domains compared to the healthy 
population. Patients who were ventilated, being in an advanced stage of the disease, scored 
about as high on quality of life as patients with Duchenne muscular dystrophy that did not start 
HMV [13]. Additionally survival increased with 5 to 10 years after starting with HMV [14]. 
Amyotrophic lateral sclerosis 
The number of patients with amyotrophic lateral sclerosis (ALS) in the Netherlands that started 
with HMV increased from 62 in 2008 to 113 in 2010. These patients chose for HMV partly 
because a randomized study showed that HMV improved quality of life and survival 
significantly [15]. In the group of patients with non-bulbar ALS, the median survival was 205 
days longer than in the group without HMV. However, patients with bulbar ALS showed no 
significant improvement in survival and quality of life. 
What to do when non-invasive ventilatory support is no longer effective? 
In progressive diseases, it is important that before HMV is initiated, patients and caregivers 
consider what to do when non-invasive ventilatory support is no longer effective. Careful 
alignment with the general practitioner and other care givers is important to anticipate the 
worsening clinical situation that is definitely going to occur. In that context it is recommended 
in conjunction with the primary responsible physician, to provide an adequate medical 
treatment, in case of shortness of breath or when HMV is no longer effective. Palliation of 
dyspnoea is often treated with morphine or midazolam. Some patients choose for euthanasia. 
If the patient chooses for HMV, this is usually for the rest of their life and this has 
consequences for the care at home, among a possible infringement on the privacy. If enough 
care at home cannot be provided for, admission in a nursing home may be necessary. For many 
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patients, however, this is not a real option. For this reason, and since admission capacity for 
HMV patients in nursing homes is low, only few patients receive HMV outside their own place 
of residence. 
Discharge and care at home 
Discharge can only take place when safety of home mechanical ventilation is guaranteed. The 
patient and all health care providers receive instructions on how to use the equipment, are 
informed about the possible alarms and the actions that have to be taken in case problems 
occur. On the day of discharge, the patient is visited at home by a specialized nurse and the 
equipment will be installed. The department of HMV can be contacted 24/7 and is always 
available in case of problems. At least once a year, both oxygen saturation and carbon dioxide 
during the night will be checked while the patient is being ventilated and when necessary this 
will be done more often. Also, at least once a year the patient will visit the outpatient clinic of 
the HMV centre. 
The general practitioner (GP) is the primary responsible physician for patients with HMV and 
the first to contact in case of problems. The activities and the role of the GP depends of the 
stage of invalidity and the progression of the underlying disease. Especially in the final stage of 
the disease, a big effort is asked of the family, caregivers, professionals and the GP to provide 
comfort [16]. 
Future 
The World Health Organization expects that by 2015, 2.3 billion people will be overweight, of 
whom 700 million with obesity. It is expected that the number of patients with obesity 
hypoventilation syndrome increases and therefore consequently the need for HMV [17,18]. 
Research in this group has shown that within one month after the initiation of HMV 
improvements in gas exchange occur. Also morning headache, dyspnoea and daytime 
sleepiness disappear. 
The second group that is eligible for HMV, are patients with COPD. After a long period in 
which the effect of HMV in this group was under discussion, there are now indications that 
HMV could be effective in patients with COPD and a high carbon dioxide level [19]. Even 
improvement in the forced expiratory volume in one second (FEV1) was demonstrated [20,21]. 
A recent Dutch randomized controlled study confirmed these results and reported an 
improvement in quality of life, 3 months after the initiation of HMV. In this study, 
rehabilitation was combined with HMV during the night, while the control group received only 
rehabilitation [11]. 
Home mechanical ventilation in the Netherlands 
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The last years there was an increase in patients who need more complex care. This 
development creates an extra demand for facilities for this group of patients, such as nursing 
homes and home care organizations. Because these patients can only survive by continuous 
ventilatory support (24/7), safety aspects are crucial. This creates increased demands of the 
organizations in combination with more stringent safety requirements for the complex care 
around these patient. Recent European research shows that the quality of care around HMV is 
significantly better in centres treating more patients [22]. It is therefore preferable to offer 
HMV primarily by designated centres of home mechanical ventilation. The expectation is that 
the number of patients with an indication for chronic ventilation will increase. We expect that 
the average growth of 10% a year that we saw over the last 20 years will continue. This growth 
in combination with a further increase of complex patients means that HMV can only be 




 Home mechanical ventilation is an effective treatment in patients with a 
neuromuscular disease and thoracic cage problem and saves costs. 
 
 The last 10 years, there is a continuous growth in the number of patients with HMV, 
81% of them receive non-invasive ventilatory support. 
 
 The increased complexity of care requires strict regulation to ensure the safety of 
patients with HMV. 
 
 Because of the expected growth of patients with obesity hypoventilation syndrome 
and the potential new group of patients with chronic obstructive pulmonary disease, 
the need for HMV will further increase. 
 
 The quality of care in patients with HMV is best in centres providing home 
mechanical ventilation to a large group of patients. 
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Home mechanical ventilation is usually started in hospital as arterial blood gas sampling is 
deemed necessary to monitor CO2 and O2 adequately during institution of ventilatory support. 
A non-invasive device to reliably measure CO2 transcutaneously would alleviate the need for 
high care settings for measurement and open the possibility for home registration.  
Objectives 
In this study we investigated whether the TOSCA
®
 transcutaneous CO2 (PtcCO2) 
measurements, performed continuously during the night, reliably reflect arterial CO2 (PaCO2) 
measurements in adults with chronic respiratory failure.  
Methods 
Paired measurements were taken in 15 patients hospitalized to evaluate their blood gas 
exchange. Outcomes were compared 30 min, 2, 4, 6 and 8 h after attaching the sensor to the 
earlobe. A maximum difference of 1.0 kPa and 95% limits of agreement (LOA) of 1 kPa 
between CO2 pressure measurements, following the analysis by Bland and Altman, were 
determined as acceptable.  
Results 
Mean PtcCO2 was 0.4 kPa higher (LOA –0.48 to 1.27 kPa) than mean PaCO2 after 30 min. 
These figures were 0.6 kPa higher (LOA –0.60 to 1.80 kPa) after 4 h, with a maximum of 0.72 
kPa (LOA 0.35 to 1.79 kPa) after 8 h. The corresponding values for changes in PtcCO2 versus 
PaCO2 were not significant (ANOVA).  
Conclusions 
PtcCO2 measurement, using TOSCA
®
, is a valid method showing an acceptable agreement 
with PaCO2 during 8 h of continuous measurement. Therefore, this device can be used to 
monitor CO2 adequately during chronic ventilatory support. 
 




Home mechanical ventilation (HMV) is an effective therapy which improves survival in 
patients with chronic respiratory failure due to neuromuscular disease and chest wall 
deformation [1,2]. Recent guidelines describe when to start with HMV [3]. In general, a 
combination of symptoms such as fatigue, headache, dyspnoea and respiratory failure (arterial 
CO2, PaCO2, >6.0 kPa) suggests that ventilatory support is indicated. Usually HMV is started 
clinically as arterial blood gas sampling is necessary to confirm the diagnosis and monitor CO2 
and O2 adequately during initiation of ventilatory support. Arterial cannulation is, however, an 
invasive and painful procedure with occasional complications including infection, vascular 
damage and thrombosis [4]. Especially in this group of patients, severe deformities sometimes 
make the procedure technically challenging. In many hospitals patients have to be admitted to 
the intensive care unit (ICU) for logistical reasons, leading to higher costs and occupation of a 
scarce facility. Home monitoring in patients with non-invasive ventilation or long-term oxygen 
therapy is therefore an interesting alternative as was shown recently [5,6]. The possibility to 
non-invasively and reliably monitor carbon dioxide in combination with oxygen saturation 
would lead to an enormous improvement of patient care and probably reduction of costs. In 
recent years, transcutaneous measurement of CO2 has become available and several different 
devices have been tested. While Storre et al. [7] used the SenTec digital monitor, Janssens et al. 
[8] showed that transcutaneous carbon dioxide (PtcCO2) can be measured with the Radiometer 
TCM-3 capnograph during 8 h and a sensor temperature of 43°C without recalibration. The 
TOSCA
®
 monitor was used in both the acute setting of non-invasive ventilation for 
exacerbations of COPD [9] and during cardiopulmonary exercise testing [10]. Transcutaneous 
monitors have been evaluated in many settings like anesthetized children [11], critically ill 
adults [12], during major surgery [13], in newborns [14] and in sleep studies [15]. However, 
until now no study has investigated whether the TOSCA
®
 PtcCO2 monitor is a valid tool to 
monitor carbon dioxide gas exchange continuously without replacing the sensor during 8 h. In 
this study we investigated whether PtcCO2 measurements, using the TOSCA
®
 PtcCO2 monitor 
continuously during the night, adequately reflect arterial blood gas assessments in adults with 







 PtcCO2 monitor is a device which non-invasively assesses CO2 levels in 
combination with standard pulse oximetry. The Institutional Review Board of our university 
approved this study. Informed consent was obtained from all participants prior to study 
inclusion. The PtcCO2 monitor is attached to the patient’s earlobe via a sensor and disposable 
clip. It warms the lobe to 42°C allowing arterialization of capillary blood and measures CO2 
using a Stow-Severinghaus-type electrode [16]. PtcCO2 is measured by determining the pH of 
an electrolyte solution that is situated between the sensor and a Teflon membrane. 
Validation of the TOSCA
®
 PtcCO2 monitor was assessed by comparing PtcCO2 by TOSCA
®
 
with PaCO2 in 15 consecutive patients. All patients were either using chronic ventilatory 
support or were expected to commence it in the near future. All patients were admitted to the 
ICU for invasive blood gas monitoring to evaluate their nocturnal gas exchange. Heparinized 
arterial blood gas samples were drawn from an arterial line every 2 h and analysed on the blood 
gas analyser ABL715 (Radiometer Medical ApS, Brønshøj, Denmark). Paired samples were 
taken from the radial artery and compared with transcutaneous monitor readings every 2 h. 
Thirty minutes after the sensor was attached, the first PtcCO2 was determined, while at the 
same time the first arterial sample was taken. Subsequent paired measurements were taken at 2, 
4, 6 and 8 h. Although the TOSCA
®
 device presents continuous readings, only the paired 
samples with the same interval as the arterial blood gas samples were used for the analysis. 
Statistical Analysis 
The method of Bland and Altman [17] was used to assess agreement between the arterial blood 
gas and transcutaneous variables . A maximum bias of 1.0 kPa (7.5 mm Hg) and 95% limits of 
agreement (LOA) of 1.0 kPa (7.5 mm Hg) between transcutaneous and arterial carbon dioxide 
pressure measurements were determined as acceptable. A maximum bias of <2 and 95% LOA 
of 4% were determined as clinically acceptable between arterial oxygen and transcutaneous 
saturation. To determine whether transcutaneous measurements differ significantly from the 
arterial values at the same time point we performed a Student’s paired t test [10]. Analysis of 
variance for repeated measurements was used to determine changes from one time point to the 
next. Data analysis was performed with SPSS version 15 (SPSS Inc., Chicago, Ill., USA) and 
MedCalc for Windows, version 9.5.0.0 (MedCalc Software, Mariakerke, Belgium). 
  




Eight women and seven men with a mean (SD) age of 58 years were enrolled in the study. The 
diagnosis was neuromuscular disease in 7 patients, chronic obstructive pulmonary disease in 5 
patients and obstructive/central sleep apnoea syndrome in 3 patients. Thirteen patients received 
chronic ventilatory support and 2 were breathing spontaneously. A total of 75 paired 
measurements were taken 30 min, 2, 4, 6 and 8 h after attaching the sensor to the earlobe. 
Correlations are 0.96 after 30 min, 0.90 after 4 h and 0.91 after 8 h. To assess the measurement 
characteristics of the device, we calculated the bias and LOA as described by Bland and 








Mean (x-axis) versus difference (y-axis) of transcutaneous and arterial carbon dioxide tension according to Bland and 
Altman [17] in 15 subjects, 30 min (A), 4 h (B) and 8 h (C) after attaching the sensor to the earlobe. 
 
The mean PtcCO2 was 0.4 kPa (3 mm Hg) higher than the mean PaCO2 after 30 min. This 
difference increased slightly during the night to a maximum of 0.72 kPa (5.4 mm Hg) after 8 h. 
The LOA (bias ± 1.96 SD) ranged from –0.48 to 1.27 kPa (3.6 to 9.5 mm Hg) after 30 min, 
from –0.60 to 1.80 kPa (4.5 to 13.5 mm Hg) after 4 h and from –0.35 to 1.79 kPa (2.6 to 13.4 
mm Hg) after 8 h. At all time points the paired difference was highly correlated (p < 0.004) 
with PaCO2. The paired measurements, tested in 15 patients over 8 h, have mean values for 
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PtcCO2 – PaCO2 after 30 min of 0.39 ± 0.44 kPa (2.9 ± 3.3 mm Hg), after 4 h of 0.59 ± 0.61 
kPa (4.4 ± 0.61 mm Hg) and after 8 h of 0.72 ± 0.54 kPa (5.4 ± 4.0 mm Hg) (repeated 
measures ANOVA, p = 0.253; fig, 2).  
Figure 2. 
 
Mean values of PtcCO2 – PaCO2 and SD, in 15 patients. Drift in PtcCO2 over 8 h is not significant (ANOVA). 
 
The observed range of changes in PaCO2 during repeated measurements was –0.7 kPa (5.25 
mm Hg) to 1.3 kPa (9.75 mm Hg) and agreement among the changes in PtcCO2 and PaCO2 
was close at 0.2 kPa (1.2 mm Hg) [LOA (bias ± 1.96 SD), 1.4 kPa (–10.5 mm Hg) and 1.85 
kPa (13.7 mm Hg)], the difference was not significant. 
The mean PaO2 at baseline was 9.4 kPa (70.5 mm Hg), after 4 h 9.9 kPa (74.3 mm Hg) and 
after 8 h 10.0 kPa (75 mm Hg). Figure 3 shows the agreement between the arterial and 











Bias and LOA of arterial and transcutaneous oxygen saturation according to Bland and Altman [17] in 15 subjects, 30 
min (a), 4 h (b) and 8 h (c) after attaching the sensor to the earlobe. 
 
Arterial oxygen saturation was between 74 and 99%, while the transcutaneous oxygen 
saturation was between 76 and 99%. There was only a mean difference (bias) of maximal 0.2% 
at all time points.  
The attachment of the sensor to the earlobe was good, none of the patients showed skin 
problems due to the sensor or the resulting temperature of 42°C.  
Discussion 
This study shows that PtcCO2 measurement by the TOSCA
®
 has a clinically acceptable 
agreement with PaCO2 during 8 h of unsupervized continuous measurement. Earlier studies 
have also assessed the TOSCA
®
 system in different settings, but none have done this in a non-
supervized continual measurement, while asleep, as in our study [3,7-15,18] . All referred 
studies performed measurements with a reported mean difference (bias) between PaCO2 and 
PtcCO2 ranging from 0.4 to 1.0 kPa (3 to 7.5 mm Hg). The observed range of changes in 
PaCO2 during repeated measurements in our study was –0.7 kPa (5.25 mm Hg) to 1.3 kPa 
(9.75 mm Hg) and agreement among the changes in PtcCO2 and PaCO2 was close at 0.2 kPa 
(1.2 mm Hg). The difference in CO2 measurements between transcutaneous and arterial values 
are small and are not likely to influence the decisions in adjusting the ventilator settings. 
Measuring the SpO2 with the TOSCA
®
 sensor revealed a clinically acceptable bias between 
SaO2 and SpO2 of 0.2% difference at all time points. We believe that measuring gas exchange 
continuously in patients with chronic ventilatory support provides more information about the 
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changes over night than single arterial measurements during admission on the ICU [19] . 
Nevertheless, the transcutaneous assessment has some limitations: it lacks information on 
bicarbonate, pH and arterial oxygen, it is expensive, it needs disposable items for 
measurements and, finally, it is rather fragile. However, the advantage of not being admitted to 
the ICU provides a more realistic view of the clinical condition over night. This study suggests 
that measurement in a high care setting, such as an ICU, might no longer be necessary in many 
patients, thus saving costs. Currently, we are testing the TOSCA
®
 monitor for registration at 
home during the initiation phase of HMV, thereby alleviating even more the need for 
hospitalization and reducing costs. All personnel, whether inside or outside the hospital, 
require training before working with the TOSCA
®
 transcutaneous monitor. 
In summary, we showed that the TOSCA
®
 transcutaneous monitor can be used to replace the 
arterial sampling with clinically acceptable accuracy in adults with chronic respiratory failure 
using ventilatory support. Measuring oxygen saturation and carbon dioxide continuously 
provides more information about changes during the night than single arterial measurements. 
The sensor was well tolerated in patients during the 8-hour observation period and was not 
associated with a significant drift of the PtcCO2 signal. 
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Home mechanical ventilation (HMV) in the Netherlands is normally initiated in hospital, but 
this is expensive and often a burden for the patient. In this randomized controlled study we 
investigated whether initiation of HMV at home in patients with chronic respiratory failure is 
non-inferior to an in hospital based setting. 
Methods 
Seventy-seven patients were included, of which 38 patients started HMV at home. All patients 
were diagnosed with chronic respiratory failure due to a neuromuscular or thoracic cage 
disease. Primary outcome was the arterial carbon dioxide (PaCO2) while quality of life and 
costs were secondary outcomes. Telemonitoring was used in the home group to provide 
therapeutic information, for example; transcutaneous carbon dioxide, oxygen saturation and 
ventilator information, to the caregivers. Follow-up was six months. 
Results 
PaCO2, improved by 0.72 (SE ± 0.16) kPa in the hospital group and by 0.91 (±0.20) in the 
home group, both improvements being significant and the latter clearly not inferior. 
There were also significant improvements in quality of life in both groups, again not being 
inferior with home treatment. 
Conclusion 
This study is the first to show that initiation of HMV at home in a selective group of patients 
with chronic respiratory failure is as effective for gas exchange and quality of life as hospital 
initiation. In addition we found that it is safe, technically feasible and that more than € 3000 
per patient can be saved compared to our standard care. 




Home mechanical ventilation (HMV) in the Netherlands routinely starts in a clinical setting as 
recommended in the national guideline and typically requires several days, up to a week of 
hospitalization [1]. Nocturnal arterial blood gas analysis while on HMV complete the initiation 
period and are performed at the intensive care. It is intuitive that the costs of starting HMV in a 
hospital setting are substantial higher than at home which is the topic of our study. In addition 
being admitted to a hospital for patients is not only an emotional burden, it also increases the 
risk of developing a nosocomial infection [2]. Patients on HMV are mostly severely disabled 
and it is often, perhaps paradoxically, challenging to provide the same high level of 
individually tailored care in hospital as compared to home. These are all very important 
reasons to investigate whether the initiation of HMV cannot be carried out in the home setting. 
A problem of the initiation of HMV at home so far has been the lack of professional 
supervision in the home environment and night time observation during sleep. A probable 
solution for this problem is the use of telemonitoring to transmit digital data and provide 
clinical health care outside the hospital [3] and [4]. The data in patients with HMV comprises 
of ventilator settings and physiological data, for example carbon dioxide and oxygen saturation 
levels. It has been shown that telemonitoring can be cost-effective and in certain settings is able 
to transfer the burden of care from health-care professionals to family and home-care personnel 
[5]. In the latter study patients with chronic obstructive pulmonary disease (COPD) on oxygen 
or HMV were monitored by tele-assistance which reduced both hospitalizations and urgent 
calls compared to the control group that received standard care. 
As we do not know if the initiation of HMV at home is effective, technically feasible and cost-
effective we set up a randomized controlled trail. 
Our hypothesis was that initiation of HMV at home, by using telemonitoring, in a selective 
group of patients with chronic respiratory failure due to neuromuscular disease (NMD) or 
thoracic cage disorder is not inferior compared to initiation in a hospital. The primary outcome 




The study design was single-centre, prospective, randomized and controlled. Patients 
diagnosed with chronic respiratory failure due to a NMD or thoracic cage disorder being 
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referred to our outpatient clinic were screened for participation in this study. Chronic 
respiratory failure was defined as daytime PaCO2 > 6.0 kPa (> 45 mmHg) [6] and [7] with 
complaints of respiratory failure (pulmonary infections, headache, daytime sleepiness, 
concentration problems) as stated in our national guideline [1]. Patients with orthopnoea due to 
diaphragm paralysis and daytime normocapnia were also included. Patients younger than 18 
years, those who needed invasive ventilation and the ones that lived in a nursing home were 
excluded. We excluded patients with strictly COPD as HMV is not a standard therapy in the 
Netherlands in those patients. Patients not naïve to a mask, for example failure after CPAP 
therapy and patients with an acute episode of respiratory failure were also excluded. The study 
was approved by the Medical Ethics Committee of the University of Groningen, University 
Medical Centre of Groningen and written informed consent was obtained from all patients. The 
trial was registered with the Netherlands Trial Registry (NTR number 1476). 
Randomization and intervention 
Patients started HMV at home or in the hospital in random order. Stratification was done for 
patients with Amyotrophic Lateral Sclerosis (ALS) to prevent a possible imbalance between 
the two groups. Randomization was done by an independent statistician using a stratified block 
randomization with a block size of 6. 
Measurements 
Daytime arterial blood gasses were taken from the radial artery, in sitting position and without 
oxygen supplementation or HMV at baseline and 6 months after the initiation of HMV at the 
outpatient clinic. 
Patients completed the following questionnaires: Severe Respiratory Insufficiency (SRI) [8], 
Maugeri Respiratory Failure (MRF-28) [9], Hospital Anxiety and Depression Scale (HADS) 
[10] and the Short-Form Health Survey (SF-36) [11].The SRI contains seven domains; 
respiratory complaints, physical functioning, attendant symptoms and sleep, social 
relationships, anxiety, psychological well-being and social functioning. The MRF contains 
three domains; daily activity, cognitive function and invalidity. The HADS contains the anxiety 
and depression domain. The SF-36 contains eight domains; physical functioning; role physical; 
bodily pain; general health; vitality; social functioning; role emotional and mental health. 
Forced vital capacity was measured by spirometry (Masterscreen
®
 Viasys, Bodystat Ltd, Isle of 
Man, UK.). 
Carbon dioxide and oxygen saturation were assessed through the skin of the earlobe, by 
TOSCA
®
 (Linde Medical Sensors AG. Basel. Switzerland) [12]. 
A standard procedure describing the technical setup of HMV was used both at home and in the 
hospital. All patients started with the Elisée 150
®
 ventilator (ResMed Paris, Fr.). The choice of 
the interface could be a nasal, full-face, mouth or total-face mask. The ventilator in the pressure 
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mode was set up at the start with an inspiratory pressure of 10 cm H2O; a positive end 
expiratory pressure (PEEP) of 4 cm H2O; a target volume of 8–10 ml/kg and a ventilatory rate 
close to the patients breathing frequency. The set up in the volume mode started at a volume of 
8–10 ml/kg; a PEEP of 4 cm H2O and a ventilatory rate close to the patients breathing 
frequency. The standard procedure described which actions should be taken to change the 
ventilator settings during the initiation of HMV. For example, if the patient needed more air, 
the inspiratory pressure was increased and if the patient snored during the PEEP was increased. 
During the initiation of HMV adjustments to the ventilator and or interface were done to 
improve the blood gasses and the patients comfort resulting in a good night sleep. 
Initiation of home mechanical ventilation in the hospital 
Standard care during the initiation of HMV in our hospital entails admission on a regular 
respiratory ward with specifically trained personnel. The first day of admission the patient 
started HMV with the intention to get used to the interface and to adjust to the ventilator 
settings. Patients were instructed to use the ventilator as long as possible during the first night. 
They were allowed to stop the HMV during the night and if applicable start again early in the 
morning for another session. Every day the necessary actions including, adjusting ventilator 
settings or interface were performed. The patient had to sleep at least 6 h with the ventilator, 
before he was transferred to the intensive care unit (ICU) to assess arterial blood gasses, 
through a radialis catheter, during the night while using the HMV. The latter being the standard 
routine in the Netherlands. If normalization of carbon dioxide and oxygen saturation levels 
while on the ventilator were reached, the patient was discharged. The ventilator was installed at 
home by a nurse of the department of HMV. After two months the patient was admitted again 
to the ICU for nocturnal arterial blood gas assessment while on HMV. The patient had to bring 
their own home ventilator to the hospital. 
Follow-up was six months after starting HMV at the outpatient clinic to assess an arterial blood 
gas analysis and lung function. 
Initiation of HMV at home started during the first visit at the patient's home by the nurse 
practitioner (NP). The ventilator, humidifier and transcutaneous monitor were installed in the 




Figure 1. Setup of the telemonitoring equipment at home. 
 
Ventilator Elisée 150®, humidifier Fisher and Paykel HC 150®, transcutaneous monitor TOSCA®, laptop with mobile 
connection. 
 
This installation also included the laptop, mobile connection and the software program that was 
used to send digital data of the devices to the hospital. The first time the patient was ventilated 
the NP was present. After instruction was given to the patient and if necessary to the caregivers 
they practiced the HMV themselves at daytime. If in the first night, when trying to sleep with 
the HMV, the patient woke up and could not continue because of discomfort they were allowed 
to stop. The following days and nights they tried to extend the number of hours on HMV. 
Patients were instructed to call the department of HMV 24/7 if problems occurred. If sputum 
mobilization was a problem patients were instructed to use air stacking and one ventilator 
mode was adjusted for mouthpiece ventilation. Every day the ventilator information (e.g. 
volume, frequency, pressure levels, hours ventilator was used) was sent to the hospital and 
evaluated by the NP. The NP informed the patient about the results over the telephone and if 
necessary the ventilator settings were adjusted by the patient or the care giver. Changing the 
ventilator settings while on the phone with the NP is part of the instruction at the start of HMV. 
The transcutaneous monitor was attached the moment the patient could sleep for six hours 
while being on HMV. The next day the measurements of the transcutaneous monitor and the 
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ventilator were evaluated, by using telemonitoring. When the results showed a normalization of 
the carbon dioxide and oxygen saturation, the initiation period was ended during a house call 
by the NP. The transcutaneous monitor and the telemonitoring equipment were returned to the 
hospital. Two months after the initiation of HMV, transcutaneous monitoring at home was 
performed again. 
Follow-up was six months after starting HMV at the outpatient clinic to assess an arterial blood 
gas analysis and lung function. 
Telemonitoring 
Every morning during the initiation period of HMV at home, the data of the ventilator and if 
applicable of the transcutaneous monitor was sent to the hospital. The data comprized of 
ventilator settings, respiratory rate and carbon dioxide and oxygen saturation levels. The NP 
received the anonymized digital data by email and phoned with the patient to evaluate the 
results. A laptop was used to transfer the information collected by the ventilator and 
transcutaneous monitor to the hospital. A software program especially developed for this study 
started the data collection of the ventilator and transcutaneous monitor automatically. 
Cost analysis 
Units of health care consumption that were registered included admission days to the general 
ward and ICU, time spent by the nurse practitioner (including house calls) and travelling 
expenses. Volumes of health care consumption were multiplied with their cost prices according 
to the Dutch guideline for cost studies [13]. The 2012 price level was used. Costs are displayed 
in Euro's (€). The time horizon of the cost study was equal to that of the clinical study and was 
6 months. Mean total costs per patient were calculated for both interventions separately. 
Confidence intervals (95%CI's) were computed based on bootstrap re-sampling with 5000 
replications of the trial dataset. 
Statistical analysis 
The primary outcome analysis was PaCO2 which was based on intention-to-treat (ITT) 
analysis. The power analysis was based on a non-inferiority test of the difference of two 
means. With an alpha of 0.05, a beta of 0.2, a standard deviation off 0.71 and a maximum 
difference in PaCO2 of 0.5 kPa, it was necessary to have two groups off 26 patients. A paired-
sample T-test was performed to determine the difference within groups and an independent-
sample T-test for the difference (Δ) between groups. The level of statistical significance was 





380 patients started non-invasive HMV in the University Medical Centre of Groningen 
(UMCG) during the inclusion period which lasted from 2008 till 2012 (Fig. 2). 
  






- declined due to the burden to care givers at home 
(n=5)
- wanted to be hospitalised (n=1)














- therapy failure (n=2)
- deseased (n=2)
- no bloodgas analysis (n=3)
- disappointment after randomisation (n=1)
Dropped out (n=8)
- therapy failure (n=2)
- deseased (n=5)
- sputum problems after starting     
ventilatory support (n=1)
Chronic respiratory failure referred to 
department of home mechanical ventilation
(n=380)
Screen failures (n=296)
- acute admission (n=105)
- COPD (n=90)
- BIPAP after CPAP failure (n=84)




Home group: initiation of home mechanical ventilation at home. Hospital group: initiation of home mechanical 
ventilation in the hospital. COPD: chronic obstructive pulmonary disease. BIPAP: bi-level positive airway pressure. 
CPAP: continuous positive airway pressure. 
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Of the 84 patients that were eligible, 77 were randomized (Table 1).  
 
Table 1. Baseline characteristics. 
 Home group (n=38) Hospital group (n=39) 
Male 20 25 
Age in years 59.9 ± 12.6 56.9 ± 13.9 
Neuromuscular disease 33 35 
Thoracic cage disorder 5 4 
Body mass Index kg-m
2
 27 ± 6.3 27 ± 6.8 
Blood gas analysis room air 
      Ph 7.40 ± 0.3 7.40 ± 0.3 
      PaCO2 kPa 6.6 ± 0.9 6.6 ± 1.1 
      PaO2 kPa 10.0 ± 1.7 9.5 ± 1.3 
      SaO2 % 95 ± 2.9 94 ± 2.7 
      HCO3 mmol/l 30.2 ± 3.8 30.4 ± 3.8 
VC % predicted 50.3 ± 20.9 51.6 ± 18.1 
FEV1 / VC 79.3 ± 12.2 81.2 ± 15.7 
Pack years 14.3 ± 11.2 29.5 ± 17.8 
Current smokers 2 3 
Wheelchair-bound 16 12 
 
Data are presented as n or mean ± SD. 
kPa: kilopascal. Ph: acidity level. PaCO2: partial pressure of arterial carbon dioxide. PaO2: partial pressure of arterial 






Eight in each group withdrew during follow-up (Table 2). 
 
Table 2.  Drop-out with reasons. 
 Diagnosis Reason 
Home group  
1 Morbus Steinert Developed lung cancer 
2 Amyotrophic lateral sclerosis Death due to progression disease 
3 Amyotrophic lateral sclerosis Euthanasia  
4 Amyotrophic lateral sclerosis Palliative sedation 
5 Amyotrophic lateral sclerosis Palliative sedation 
6 Amyotrophic lateral sclerosis Euthanasia  
7 Primary lateral sclerosis Not compliant to home mechanical ventilation 
8 Diaphragm paralysis Paralysis recovered   
Hospital group  
1 Amyotrophic lateral sclerosis Disappointment after randomization 
2 Diaphragm paralysis Not compliant to home mechanical ventilation 
3 Von Recklinghausen type 1 Not compliant to home mechanical ventilation 
4 Amyotrophic lateral sclerosis Arterial blood gas analysis not possible 
5 Amyotrophic lateral sclerosis Death due to progression disease 
6 Amyotrophic lateral sclerosis Palliative sedation 
7 Amyotrophic lateral sclerosis Arterial blood gas analysis not possible 
8 Amyotrophic lateral sclerosis Arterial blood gas analysis not possible 
 
The largest group in this study was diagnosed with ALS (4 with bulbar involvement); 10 
patients in the hospital group had diaphragm paralysis and 4 in the home group. Two patients 
crossed from intervention, one in the hospital group and the other in the home group. They 
remained in the initial group for all ITT analysis. Both analysis per protocol and ITT did not 
resulted in different outcomes. We also evaluated the variety in diagnoses and did not find a 
significant difference between both groups. 
One patient with limb girdle dystrophy in the home group and 1 patient with ALS in the 
hospital group used HMV when their blood gasses were assessed during 6 months follow-up 
due to the progression of their illness. 
In the home group 5 patients died versus 2 in the hospital group. In no case was this due to 
technical problems in the home settings. Patients died varying from one week up to almost 6 
months after starting HMV, all experiencing a non-acute progression of their disease (ALS). 
Twenty-five patients in the home group and 28 patients in the hospital group were not able to 
perform physical activities regarding the maintenance of HMV. The care givers were instructed 
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during the initiation of HMV at home while this was done after being discharged in the hospital 
group. 
Blood gas analysis and ventilator settings 
Daytime PaCO2, the primary endpoint, improved by 0.72 (SE ± 0.16) kPa in the hospital group 
and by 0.91 (± 0.20) in the home group being not significantly different between both groups 
(Table 3).  
 
Table 3. Changes in daytime arterial blood gasses and lung function pre home mechanical 
ventilation to 6 months after the start. 
 
Home group (n=30) Hospital group (n=31) 
Between 
groups 
 Baseline  Follow-up  P-Value* Baseline  Follow-up  P-Value* P-value¶ 
Ph 7.40 ± 0.3 7.40 ± 0.3 0.261 7.40 ± 0.3 7.40 ± 0.3 0.913 0.423 
PaCO2 (kPa) 6.6 ± 0.9 5.7 ± 0.8 0.000 6.6 ± 1.1 5.9 ± 0.8 0.000 0.631 
PaO2 (kPa) 10.0 ±1.7 11.3
 ± 2.2 0.002 9.5 ± 1.3 10.3 ± 1.7 0.015 0.579 
SaO2 % 95 ± 2.9 96 ± 1.9 0.020 94 ± 2.7 95 ± 3.6 0.348 0.598 
HCO3 (mmol/l) 30.2 ± 3.8 26.6 ± 3.1 0.000 30.4 ± 3.8 26.9 ± 2.5 0.000 0.996 
aBE 4.9 ± 2.6 2.6 ± 1.7 0.000 4.8 ± 2.8 2.2 ± 1.8 0.000 0.283 
VC (% pred) 51.6 ± 22.8 53.4 ± 21.8 0.528 52.4 ± 18.5 49.8 ± 19.0 0.301 0.428 
 
Data are presented as n or mean ± SD. 
kPa: kilopascal. Ph: acidity level. PaCO2: partial pressure of arterial carbon dioxide. PaO2: partial pressure of arterial 
oxygen. SaO2: arterial oxygen saturation. HCO3: bicarbonate. VC: vital capacity. Follow-up: six months after the 
initiation of home mechanical ventilation. 
Bold: p < 0.05 significant change. 
  P-value* refers to paired t test analysis form starting ventilatory support to six months follow-up within each group. 




Nocturnal transcutaneous registration showed an improvement in both groups, both after 
initiation and after two months (Table 4). 
 
Table 4. Changes in nocturnal transcutaneous carbon dioxide and oxygen saturation. 














tcpCO2 (kPa) 7.6 ± 1.0 6.5 ± 0.9 5.8 ± 0.7 7.4 ± 1.3 6.4 ± 0.8 5.7 ± 0.7 
Maximal tcpCO2  (kPa) 8.7 ± 1.4 7.3 ± 0.9 6.7 ± 0.8 8.4 ± 1.8 7.3 ± 0.9 6.6 ± 0.2 
Oxygen saturation (%) 91.3 ± 5.1 95.2
 ± 1.8 96.2 ± 1.8 91.8 ± 4.9 95.7 ± 1.7 95.9 ± 1.7 
Lowest oxygen 
saturation (%) 
74.6 ± 15.2 86.6 ± 8.2 84.7 ± 12.8 74.4 ± 14.6 84.1 ± 9.2 85.7 ± 7.2 
 
Data are presented mean ± SD.  
tcpCO2: transcutaneous carbon dioxide. kPa: kilo pascal 
 
Both groups started with the same ventilator settings and only minor adjustments were needed 
during the follow-up of six months (Fig. 3).  
 
Figure 3. Ventilator settings. 
 
 
Ventilator settings from initiation to six months follow-up. Insp. pres: inspiratory pressure in cm H2O above peep. 
PEEP: positive end expiratory pressure in cm H2O. Frequency: ventilator frequency. Initiation: after the initiation of 
home mechanical ventilation. Follow-up: 6 months follow-up after starting home mechanical ventilation. 
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Three patients were ventilated in the volume mode and the other 74 in the pressure controlled 
mode. In the home group a mean of 11 (±1.86) days was needed to initiate HMV and in the 
hospital group 8 (±0.54) days. Follow-up after 6 months showed that patients at home slept a 
mean of 10.0 (±0.83) hours with HMV and the hospital group 8.5 (±0.67) hours. 
Health related quality of life 
The hospital and home group improved significantly on two of seven SRI subscales. The 
improvements in SRI score form baseline to six months follow-up were not inferior (or 
significantly better) in the home group compared to the hospital group. 
The MRF-28 showed a significant improvement in the hospital group on the total score but not 
in the home group, however not being significantly different between both groups. The other 
MRF-28 domain scores were both within and between groups not significantly different. The 
HADS showed no significant changes both within and between groups. The SF-36 showed a 
significant improvement in the domain vitality in both groups. The other SF-36 domains 
showed no significant changes between groups (Table 5). 
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Table 5. Changes in health related quality of life measurements pre home mechanical 
ventilation to 6 months after the start. 
 
Home group (n=30) Hospital group (n=35) 
Between 
groups 
 Baseline Follow-up P-Value* Baseline Follow-up P-Value* P-value¶ 
SRI        
RC 47.6 ± 19.5 55.5 ± 17.3 0.023 48.6 ± 18.5 51.9 ± 17.6 0.114 0.462 
PF 28.8 ± 21.4 31.9 ± 21.5 0.994 36.6 ± 20.5 32.9 ± 20.5 0.452 0.585 
AS 55.1 ± 18.6 69.6 ± 18.0 0.000 48.5 ± 19.1 60.9 ± 16.7 0.000 0.904 
SR 68.5± 12.3 69.5 ± 12.7 0.723 71.2 ± 12.8 66.9 ± 11.8 0.204 0.247 
AX 55.0 ± 21.1 57.8 ± 24.2 0.474 54.7 ± 16.8 60.9 ± 16.7 0.159 0.628 
WB 57.1 ± 19.8 57.3 ± 24.0 1.000 60.3 ± 15.7 59.7 ± 18.3 0.946 0.963 
SF 52.7 ± 19.1 51.9 ± 22.3 0.298 57.2 ± 17.5 55.1 ± 18.5 0.733 0.603 
SS 52.1 ± 14.4 56.2 ± 16.4 0.153 53.9 ± 12.3 55.4 ± 12.0 0.248 0.762 
MRF-28        
Daily activities 58.1 ± 27.9 59.7 ± 27.6 0.741 60.3 ± 29.0 53.2 ± 28.1 0.182 0.706 
Cognition 35.0 ± 32.6 29.4 ± 33.5 0.372 37.1 ± 35.4 30.0 ± 34.7 0.143 0.836 
Invalidity 53.3 ± 38.5 61.3 ± 37.1 0.241 57.1 ± 34.7 57.1 ± 34.7 1.000 0.333 
Total score 52.1 ± 21.1 49.2 ± 23.1 0.466 58.2 ± 19.7 45.2 ± 20.9 0.000 0.038 
HADS        
Depression 6.6 ± 4.2 6.0 ± 4.5 0.319 7.1 ± 3.5 6.4 ± 4.2 0.139 0.985 
Anxiety 6.4 ± 4.7 6.1 ± 4.9 0.193 6.8 ± 3.8 6.1 ± 3.4 0.195 0.589 
Total score 13.0 ± 8.0 12.1 ± 8.7 0.660 13.9 ± 6.8 12.5 ± 7.1 0.175 0.760 
SF-36        
PF 13.2 ± 18.5 15.6 ±19.1 0.832 17.1 ± 22.1 18.8 ± 23.6 0.784 0.983 
RP 15.7 ± 33.6 25.0 ±35.9 0.565 13.1 ± 24.4 25.7 ± 35.0 0.013 0.337 
BP 66.8 ± 30.7 66.1 ± 29.6 0.853 64.2 ± 29.2 60.5 ± 24.5 0.612 0.863 
GH 30.7 ± 24.8 35.2 ± 27.2 0.805 30.2 ± 17.3 36.0 ± 19.6 0.058 0.205 
VT 39.0 ± 21.4 52.1 ± 22.6 0.004 36.5 ± 18.9 45.2 ± 18.9 0.004 0.967 
SF 52.6 ± 32.9 58.7 ± 32.8 0.881 55.0 ± 21.7 60.3 ± 27.3 0.338 0.602 
RE 54.3 ± 52.8 57.4 ± 47.0 0.508 48.2 ± 46.3 57.1 ± 45.4 0.209 0.864 
MH 66.3 ± 21.8 72.2 ± 22.0 0.040 64.7 ± 17.5 69.7 ± 17.0 0.055 0.993 
 
Data are presented as n or mean ± SD  
SRI: Severe Respiratory Insufficiency (0 = worst possible health 100 = best possible health) respiratory complaints 
(RC), physical functioning (PF), attendant symptoms and sleep (AS), social relationship (SR), anxiety (AX), 
psychological well-being (WB), social functioning (SF), summary score (SS) 
MRF-28: Maugeri Respiratory Failure (0 = best possible health 100 = worst possible health) 
HADS: Hospital Anxiety Depression Scale (total score: 0 = best possible health 42 is worst possible health; separate 
score 0-21)  
SF-36: Short-Form Health Status Survey (0 = worst possible health 100 = best possible health) PF = physical 
functioning, RP = role physical; BP = bodily pain; GH = general health; VT = vitality; SF = social functioning; RE = 
role emotional; MH = mental health. 
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Bold: p <0.05 significant change. 
   P-value* refers to paired t test analysis form starting ventilatory support to six months follow-up within each group.  
   P-value¶ for difference in change ∆ from baseline between groups. 
Costs 
Due to the travel time in the home group the total invested time by NP per patient was 
91 min longer compared to the hospital group. In contrast the contact time per patient in the 
hospital group was higher (Fig. 4). The NP visited the patient the first day and if necessary the 
following days. This was not specified in the standard procedure and resulted in a mean of 3 
visited during the initiation period of HMV. 
 
Figure 1. Time spent during initiation of home mechanical ventilation and 6 months follow-up. 
 
Contact: direct contact between the patient and the care giver of the department of home mechanical ventilation from 
initiation to 6 months follow-up. Travel time: driving time between hospital and patient during house calls. Total: is all 
time added up. 
 
Total mean costs per patient amounted to € 726 per patient in the home group and to € 3913 in 
the hospital group (difference - € 3187; 95% CI - € 3643 to - € 2694). Mean costs in the 
hospital group amounted to € 3618 for admission to the ICU and the ward, €198 for contact 
with the NP and € 97 for travelling expenses. Mean costs in the home group included € 192 of 
travelling expenses, € 266 of house calls and consult by telephone by the nurse practitioner, 
and € 268 for hospital admissions. As the other costs; masks, ventilator, disposables supply and 
transcutaneous measurement were similar in both groups this was not accounted for. 
Telemonitoring 
Since the procedure of initiation of HMV at a distance, i.e. at home, is new and the software 
program for telemonitoring was specifically developed for this study, patients were instructed 
to contact the 24/7 call service of the HMV department if necessary. The use of telemonitoring 
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did not result in problems or calls during the night. Adjusting ventilator settings, while 
interacting with the patient or caregivers, went well after good instructions during the initiation 
process. 
Technical problems did occur initially in 11 out of the 38 patients who started HMV at home. 
In 3 patients the wireless connection was not successful because of insufficient mobile 
connection facilities as our part of the country is not very densely populated. Another reason 
was that patients with ALS sometimes live in an iron surfaced mobile unit, with bedroom and 
washroom facilities on the ground floor. The iron surface disturbs the mobile connection. In 
these 11 cases the evaluation of the patients' condition was done on individual clinical 
parameters; sleeping time with HMV, sleep quality and improvement of quality of life during 
the day. 
Discussion 
This is the first study showing that initiation of home mechanical ventilation at home, in a 
selective group of patients with a stable respiratory problem, resulted in improvements in blood 
gasses and quality of life being not inferior to in hospital initiation. In addition it showed that 
the start of HMV at home, by using telemonitoring, was safe, feasible and cheaper. 
Publications concerning the initiation of HMV outside the hospital by using telemonitoring are 
scarce. One study showed a reduction in health care utilization in patients with ALS after using 
home telemonitoring [14]. Initiation of HMV was done in the hospital and the follow-up was 
carried out at home by using telemonitoring. They used a fixed telephone line with limited 
speed of data transferral. In our study we started HMV at home and we used a mobile 
connection allowing us to move the equipment from one patient to the other without technical 
workout delays. Another study showed that telemonitoring can be more effective in patients 
who are more compliant to the therapy [15]. The installation of the telemonitoring system at 
the patient's home in our study was self-supporting meaning that the data transfer was not 
dependent on the technical skills or actions to be taken by the patient or compliance to therapy. 
A third study compared the initiation of HMV between inpatient and outpatient titration but did 
not use telemonitoring [16]. The improvement of blood gasses was equivalent between the two 
groups which is comparable to our study. However patients included in our study had a mean 
PaCO2 of 6.6 kPa while in the study of Chatwin patients had near normal daytime PaCO2. 
Our data provides a good example in the field of implementation of telemonitoring while not 
all studies have been successful so far. We believe that the results of this study contribute to the 
fact that the use of modern technologies in patients with a chronic disease can lower the burden 
to the health care system. 
Earlier studies showed an improvement in blood gasses after the initiation of HMV [17] and 
[18]. We found a comparable improvement in blood gasses in both groups indicating that the 
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initiation of HMV can be performed effectively at home in a selective group of patients with 
chronic respiratory failure due to a neuromuscular disease of thoracic cage disorder. 
Nevertheless it is obvious that a thorough scan of the home environment must be performed 
before starting HMV. 
This study also showed that it is possible to initiate HMV at home in patients with an age 
varying from 19 to 80 years of age. The youngest and the oldest started HMV at home and we 
did not notice any age related problems. In some cases the absence of a partner or family 
member resulted in recruiting home care professionals to support the patient during the first 
steps of HMV at home. In the home group patients started HMV one week after being included 
and in the hospital group this was 3 weeks. This delay in the hospital group was due to limited 
number of beds in the hospital. 
As in our centre the initiation of HMV is done in a hospital based setting and therefore 
expensive, the present study was performed to search for an alternative. The medical ethics 
committee agreed to initiate HMV outside the hospital directly instead of starting in an 
outpatient clinic or on a ward without ICU admission first. This was done to save time and to 
facilitate patients to stay at home. Initiating HMV at home was not only effective and safe, it 
was also cost-effective. This study showed a mean reduction of € 3187 per patient when HMV 
started at home. Mobile data communication costs were negligible and variable and therefore 
not included in the total costs analysis. Since we initiate HMV in the Netherlands in 
approximately 600 patients per year [19], full implementation nationwide would save over € 
1.8 million annually. Despite this enormous cost reduction we should stress the point that the 
inpatient initiation is very expensive being primarily due to the ICU admission. When the 
initiation is done on a non-ICU ward the benefit in costs would be lower compared to our 
situation. 
Despite these positive results this study has some limitations. 
Above all, there was a large group of patients with chronic respiratory failure that did not 
participate in this study for various reasons (Fig. 1). We excluded all patients with COPD as 
providing HMV to this group is still not current practice in our country. A recent meta-analysis 
showed that HMV in stable patients with COPD did not improve gas-exchange, lung function 
or QOL [20]. In this study only 2 patients with OHS were enrolled which is remarkable 
considering the growth of patients with OHS that start HMV [21]. The reason was that 27 
patients with OHS had to start with HMV in hospital immediately due to an acute respiratory 
failure. 
Secondly, the effect of HMV with regard to quality of life (QOL) in our total group compared 
to previous studies seems to be less positive. Probably this is due to the large number of ALS 
patients included in our study, which was over the 35%. Although Bourke concluded that 
HMV in ALS does improve QOL, this was based on the increased duration of time (compared 
to control group) that the QOL was maintained above 75% of their baseline value [22]. As we 
assessed absolute values of QOL it is difficult to compare both studies. If we excluded the ALS 
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group we did find a significant improvement in several domains being comparable with the 
previous studies. 
Another limitation of this study was that the initiation of HMV was done by just one NP in the 
home group. As we cannot conclude, based on this single study, that it can be duplicated in all 
other situations, we recommend an additional study were the implementation of this concept on 
a broader scale i.e. other regions, settings and with more people involved should be examined. 
Improvements in the technical and digital opportunities, during the last couple of years, will 
facilitate the development of future telemonitoring studies. Especially the use of 
polysomnography and microchip cards with detailed ventilator information, can be of great 
importance in future studies to better evaluate the patient-ventilator interaction. 
Conclusion 
In summary we showed that initiation of HMV at home in a selective group of patients with 
chronic respiratory failure due to neuromuscular disease or thoracic cage disorder is effective 
for gas exchange and quality of life and is not less effective than initiation in the hospital. In 
addition we found that it is safe and that more than € 3000 per patient can be saved. From a 
patients' perspective it is an ideal treatment as they do not have to be admitted to the hospital 
and their highly individualized care can be maintained during the initiation of HMV. 
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Most patients with amyotrophic lateral sclerosis (ALS) develop respiratory insufficiency in the 
advanced stage of their disease. Non-invasive ventilation (NIV) is commonly regarded to be a 
treatment that is effective in reducing these complaints. 
Objectives  
To assess whether the effect of NIV on gas exchange and quality of life (QOL) is different in 
patients with ALS versus without ALS. 
Methods: A post-hoc analyses was done with data from a previously published trial, in which 
all patients were instituted on NIV. Arterial blood gasses were assessed next to QOL by 
generic as well as disease specific questionnaires. 
Results 
77 Patients started NIV; 30 with ALS and 47 without. Both groups showed significant 
improvements in blood gasses after 2 and 6 months. Compared to the non-ALS group, the ALS 
group had significantly worse scores after 6 months in MRF-28, SRI, HADS and SF-36 than 
the non-ALS group.  
Conclusion 
This study shows that NIV improves gas exchange, both in patients with and without ALS. 
QOL improves markedly more in patients without ALS than in those with ALS, in whom only 
some domains improve. Our observation of little or no effect in ALS patients warrants a large 
study limited to ALS patients only. 




Most patients with amyotrophic lateral sclerosis (ALS) develop complaints of dyspnoea, 
fatigue, unrefreshing sleep and morning headache in the advanced stage of their disease due to 
respiratory insufficiency. Chronic ventilatory support is commonly regarded to be a treatment 
that is effective in reducing these complaints. 
Several studies presented data regarding the effects of chronic ventilatory support on quality of 
life (QOL) in patients with ALS. Some were positive, while others produced more reservations 
regarding chronic ventilatory support in these patients. In 2001, in a prospective study, QOL 
following non-invasive ventilation (NIV) was assessed with two questionnaires, the ALS 
functional rating scale-respiratory version (ALSFRS-R) and the Short Form 36 (SF-36) [1]. 
Early intervention of NIV resulted in an improved vitality compared to standard care in this 
study. In 2003, Bourke et al. presented the results of a cohort study on indications and effect of 
NIV on QOL in ALS patients. They used the SF-36 to assess QOL in 10 participants using 
NIV. In this study, the use of NIV was associated with an improved QOL and survival [2]. 
Finally, a third cohort study on the effects of NIV on ALS patients showed that one month after 
starting chronic ventilatory support, both blood gasses and QOL improved [3]. In 2006, Bourke 
assessed the effect of NIV, QOL and survival in participants with ALS in a randomized 
controlled trial [4]. Their conclusion was that NIV use in patients without bulbar dysfunction 
was associated with an improved QOL in some domains and a longer maintained QOL above 
75 % of the pre-randomization QOL assessed by SF-36. Despite the results mentioned above, 
Piepers et al. concluded in their review that these studies on the use of NIV in patients with 
ALS differ considerably in design and endpoint definitions and that well-designed randomized 
controlled trials are, to their opinion, not available [5]. 
We agree with the notion that more well-designed studies are needed on the effect of chronic 
ventilatory support in relation to QOL in patients with ALS. An additional point of concern is 
that in most studies, only the generic SF-36 has been used, while questionnaires set up 
specifically to assess quality of life in patients with respiratory insufficiency like the Maugeri 
Respiratory Failure (MRF-28) and the Severe Respiratory Insufficiency (SRI) were not used at 
all. Also, we believe that it is unfortunate that the previous studies did not report on outcomes 
like depression and anxiety, items frequently mentioned by patients with ALS. 
In a randomized controlled study assessing the effect on QOL of home versus in-hospital 
initiation of NIV in patients with a neuromuscular disorder (NMD) or thoracic cage problem, 
we showed an overall improvement of QOL after the start of NIV [6]. However, in this study, 
the effect size in separate diagnostic groups, such as ALS, was not assessed. It was, however, 
unique in the sense that not only the SF-36, but both the SRI and MRF-28 were used to assess 
QOL, as was the Hospital Anxiety and Depression Scale (HADS). By doing so, we created a 
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broader perspective on QOL than with only the SF-36. In the present analysis, we hypothesized 
that the effect of NIV on QOL in patients with ALS, as assessed by the SF-36, SRI, MRF-28 
and HADS questionnaires, is different compared to patients with other reasons for need of 
NIV. 
Methods 
A post hoc analysis was performed in all patients who started with NIV, from a previously 
published randomized controlled trial [6]. Patients, who had been diagnosed with chronic 
respiratory failure due to a neuromuscular disorder (NMD) or a thoracic cage problem, were 
included. The study was approved by the Medical Ethics Committee of the University of 
Groningen, University Medical Center of Groningen, and written informed consent was 
obtained from all patients. Chronic respiratory failure was defined as daytime arterial carbon 
dioxide pressure (PaCO2) >6.0 kPa (>45 mmHg). Participants started NIV at home or in the 
hospital in a randomized design. In line with our hypothesis and reassuringly, the results for 
gas exchange and QOL were not significantly different between patients who started in the 
hospital versus at home [7]. In the current analysis, we pooled all patients without ALS in one 
group and compared it to those with ALS. Gas exchange was assessed by daytime arterial 
blood gasses from the radial artery, and the following self-administered questionnaires were 
completed: SRI [8], MRF-28 [9], the SF-36 [10] and the HADS [11]. The SRI contains seven 
domains covering: respiratory complaints, physical functioning, attendant symptoms and sleep, 
social relationship, anxiety, psychological well-being and social functioning. Scores range 
between 0 and 100, with high sores representing better quality of life. The MRF-28 contains 
three domains: daily activities, cognitive function and invalidity; scores range from 0 (best) to 
100 (worse). The SF-36 contains eight domains: physical functioning, role physical, bodily 
pain, general health, vitality, social functioning, role emotional and mental health completed 
with the physical and mental component summary score 0 (worse) to 100 (best) [12]. The 
HADS contains the anxiety and depression domain; scores range from 0 (best) tot 42 (worse). 
Statistical analyses 
Independent-sample t tests were used to test for differences in change (∆) between groups from 
baseline to 6 months, and paired sample t tests were performed to assess the change within 
groups from baseline to 2 and 6 months. The level of statistical significance was set at p < 0.05. 
Statistical analyses were performed using IBM Statistics 22 (IBM, New York, USA). 
  




77 participants were randomized to start NIV at home or in the University Medical Center of 
Groningen (UMCG). For this manuscript, both groups were pooled since there were no 
differences between the results in both intervention arms, as per prior hypothesis. Thirty 
participants had ALS (grouped as ALS), the other 47 participants had a neuromuscular disease 
(diaphragm paralysis, myotonic dystrophy, limb girdle muscular dystrophy, 
facioscapulohumeral dystrophy and other) or a thoracic cage problem (kyphoscoliosis or 
obesity hypoventilation syndrome) (grouped as non-ALS). The baseline characteristics are 
presented in table 1 and show that both groups were comparable in age and gas exchange. 
 
Table 1. Baseline characteristics. 
 ALS group n=30 Non ALS group n=47 
Diagnosis  Amyotrophic lateral sclerosis Neuromuscular disease (n=42) 
Thoracic cage problem (n=5) 
Age (yr) 59.6 ± 10.6 57.7 ± 14.7 
Male (%) 66.7 53.2 
PaCO2 (kPa) 6.6 ± 0.8 6.6 ± 1.0 
PaO2 (kPa) 10.4 ± 0.9 9.6 ± 1.6 
BMI (kg/m
2
) 23.8 ± 5.2 28.9 ± 6.4 
Packyears 27.8 ± 19.4 18.9 ± 14.4 
 
Data are presented as mean ± standard deviation. 
kPa: kilopascal. PaCO2: partial pressure of arterial carbon dioxide. PaO2: partial pressure of arterial oxygen. BMI: body 
mass index. 
 
NIV was initiated in the ALS group a median of 427 (22–2582) days after being diagnosed 
with ALS. Median survival in the ALS group after the initiation of NIV was 461 (220–1451) 
days; none of the participants was still alive at the moment of our investigation. Eight patients 
in each group withdrew during follow-up, mainly due to worsening of their disease, death or 
noncompliance with NIV [7]. Both groups showed an improvement in arterial and 
transcutaneous CO2 and O2, after 2 and 6 of NIV (Table 2); however, the mean improvements 





Table 2. Changes in daytime arterial blood gasses, lung function, hours of non-invasive 


























PaCO2 (kPa) 6.6 ± 0.8 -1.2 ± 0.4
* -0.7 ± 0.3* 6.6 ± 1.0 -1.1 ± 0.2* -0.7 ± 0.2* 0.862 
PaO2 (kPa) 10.4 ± 0.9 1.8 ± 0.7
* 0.3 ± 0.4 9.6 ± 1.6 0.3 ± 0.7* 1.3 ± 0.3* 0.035¶ 
FVC (% pred) 41.6 ± 13.7 - -9.8 ± 3.7* 45.2 ± 16.6 - 2.5 ± 2.1 0.005¶ 




N=27 N=23 NIV 
initiated 
N=46 
N=43 N=42  
Hours NIV 7.7 ± 3.8 3.5 ± 1.3* 3.8 ± 1.5* 6.8 ± 1.7 0.9 ± 0.4* 1.1 ± 0.4* 0.031¶ 
tcpCO2 (kPa) 6.5 ± 0.9 -1.6 ± 0.3
* -2.5 ± 0.4 6.4 ± 0.9 -1.5 ± 0.2* -1.7 ± 0.3* 0.111 
tcSpO2 (%) 95.9 ± 1.5 3.3 ± 0.4 3.8 ± 0.5
* 95.1 ± 1.7 6.1± 1.0* 6.0 ± 1.1* 0.103 
 
Baseline data are presented mean ± standard deviation. 
Change over time are presented as mean ± standard error of mean 
¶ = p < 0.05: for difference in change between groups 0-6 months 
* = p < 0.05 for chances within groups from baseline 
kPa: kilo Pascal. PaCO2: partial pressure of arterial carbon dioxide. PaO2: partial pressure of arterial oxygen. FVC: 
forced vital capacity. FEV1: forced expiratory volume in one second. %pred: % predicted. NIV non-invasive 
ventilation. tcpCO2: transcutaneous carbon dioxide. tcSpO2: transcutaneous oxygen saturation.  
 
The mean improvement in PaO2 after 6 months was significantly lower in the non-ALS group 
compared to the ALS group. The mean number of hours on NIV increased over time in both 
groups. The ALS group used NIV for more than 11 h after 6 months and the other group 8 h 
per day (between group difference in change after 6 months p = 0.03). Some patients used NIV 
24 h per day, depending on the progression of their disease. Forced vital capacity (FVC) 
showed a significant difference between both groups after 6 months as in the ALS group, the 
FVC decreased significantly, whereas the FVC in the non-ALS group improved slightly 
(Table 2). At baseline, quality of life was higher in the non-ALS group than in the ALS group. 
Compared to the non-ALS group, the ALS group showed significantly less improvement after 
6 months on the MRF-28 total score. (Fig. 1; Table 3). 
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ALS: amyotrophic lateral scleroses. NIV: non-invasive ventilation.  
SRI: Severe Respiratory Insufficiency (0 = worst possible health; 100 = best possible health) 
MRF-28: Maugeri Respiratory Failure (0 = best possible health; 100 = worst possible health) 
SF-36: Short-Form Health Status Survey (0 = worst possible health; 100 = best possible health) 
 SF-36 PCS, physical component score; SF-36 MCS, mental component score 






Table 3. Changes in quality of life measurements after the start of non-invasive ventilation. 




















change  0-6 
months 
SRI         
Respiratory complaints 42.0 ± 16.8 6.7 ± 3.0
* 2.0 ± 4.2 51.9 ± 19.5 9.7 ± 2.0 7.3 ± 2.0* 0.194 
Physical functioning 21.0 ± 18.4 -3.0 ± 2.8 -7.9 ± 4.5 40.0 ± 19.7 2.9 ± 2.1 1.8 ± 3.0 0.075 
Attendant symp. Sleep 49.5 ± 14.6 15.2 ± 3.4
* 15.6 ± 4.1* 53.3 ± 21.3 6.5 ± 2.3 11.4 ± 2.5* 0.363 
Social relationship 68.2 ± 10.2 -0.6 ± 2.1 -6.3 ± 1.7
* 70.9 ± 13.8 1.2 ± 2.0 1.3 ± 2.3 0.032¶ 
Anxiety 47.4 ± 12.1 6.9 ± 2.7
* -6.4 ± 4.2 59.5 ± 21.0 4.3 ± 2.5 9.0 ± 2.6* 0.002¶ 
Well-being 51.2 ± 17.4 1.8 ± 2.6 0.4 ± 2.8 63.5 ± 16.6 1.0 ± 2.0 -0.1 ± 1.9 0.899 
Social functioning 44.5 ± 13.7 -2.7 ± 2.5 -7.1 ± 3.0
* 61.5 ± 18.0 1.4 ± 2.0 1.1 ± 2.1 0.027¶ 
Summary score 46.3 ± 8.7 3.5 ± 1.8 -1.4 ± 2.4 57.2 ± 14.0 3.9 ± 1.3
* 4.5 ± 1.6* 0.037¶ 
MRF-28         
Daily activities 74.0 ± 24.9 4.1 ± 2.4 5.4 ± 5.7 51.8 ± 29.2 -8.7 ± 3.6 -7.4 ± 4.3 0.083 
Cognition 34.5 ± 33.0 -9.6 ± 6.2 -4.1 ± 6.2 37.8 ± 34.9 -9.7 ± 4.6
* -7.6 ± 4.8 0.675 
Invalidity 73.1 ± 31.7 -2.3 ± 6.0 2.7 ± 5.8 44.2 ± 35.1 -2.9 ± 5.0 4.2 ± 5.5 0.867 
Total score 64.2 ± 17.9 -4.7 ± 2.4 -1.4 ± 4.2 50.2 ± 22.1 -13.0 ± 2.9
* -11.9 ± 2.9* 0.041¶ 
HADS         
Depression 8.3 ± 7.2 -0.2 ± 0.6 1.0 ± 0.6 6.3 ± 3.8 -1.3 ± 0.4
* -1.6 ± 0.4* 0.001¶ 
Anxiety 7.3 ± 4.3 0.2 ± 0.6 0.8 ± 0.7 6.3 ± 4.0 -1.2 ± 0.5
* -1.1 ± 0.4* 0.017¶ 
Total score 15.6 ± 7.2 -0.0 ± 1.1 1.8 ± 1.1 12.6 ± 7.2 -2.5 ± 0.8
* -2.7 ± 0.7* 0.001¶ 
SF-36         
Physical functioning 10.3 ± 17.6 -1.0 ± 1.4 -7.1 ± 3.2
* 18.2 ± 21.5 4.0 ± 1.3* 4.4 ± 2.0* 0.002¶ 
Role physical  6.0 ± 12.7 1.9 ± 4.6 -4.8 ± 3.3 19.7 ± 34.9 6.1 ± 6.0 17.4 ± 7.0
* 0.036 ¶ 
Bodily pain  66.9 ± 25.4 -3.8 ± 5.0 -11.4 ± 7.4 64.8 ± 32.5 -0.3 ± 4.4 3.0 ± 4.1 0.071 
General health 19.6 ± 13.6 -0.3 ± 3.1 -3.0 ± 2.8 37.2 ± 22.4 2.5 ± 2.6 7.6 ± 3.1
* 0.031¶ 
Vitality  33.6 ± 17.3 3.1 ± 3.9 4.3 ± 4.0 40.4 ± 21.4 10.6 ± 3.1
* 13.3 ± 2.7* 0.065 
Social functioning  44.4 ± 27.7 2.9 ± 6.3 -13.6 ± 5.9
* 59.8 ± 26.5 4.6 ± 3.7 11.3 ± 4.0* 0.001¶ 
Role emotional  59.8 ± 45.7 -1.3 ± 12.8 -14.3 ± 8.5 46.1 ± 51.3 13.0 ± 9.4 20.9 ± 9.1
* 0.017¶ 
Mental health  64.4 ± 20.4 -0.5 ± 2.4 0.5 ± 3.2 66.2 ± 19.4 6.0 ± 2.0
* 8.6 ± 2.5* 0.050 
Phys. comp. summary 25.7 ± 10.2 -0.8 ± 2.3 -6.8 ± 2.4
* 34.5 ± 16.7 3.1 ± 2.1 8.1 ± 2.8* 0.001¶ 
Mental comp. summary 49.4 ± 28.2 1.0 ± 7.6 -9.5 ± 5.3 47.2 ± 31.8 10.3 ± 5.6 16.6 ± 5.5
* 0.004¶ 
 
Baseline data are presented as mean ± standard deviation. 
Change over time are presented as mean ± standard error of mean 
 ¶ = p < 0.05 for difference in change between groups 0-6 months,  
* = p < 0.05 for changes within groups from baseline 
SRI: Severe Respiratory Insufficiency (0 = worst possible health; 100 = best possible health)  
MRF-28: Maugeri Respiratory Failure (0 = best possible health; 100 = worst possible health) 
HADS: Hospital Anxiety Depression Scale (0 = best possible score; 42 = worst possible score) 
SF-36: Short-Form Health Status Survey (0 = worst possible health; 100 = best possible health) 
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The sum score of the MRF-28, SRI, HADS and SF-36 improved significantly in the non-ALS 
group after 6 months, whilst in the ALS group, only the sum score of theSF-36 improved 
significantly after 6 months (Table 3). QOL in the ALS group even deteriorated as expressed 
by the sum scores of the MRF-28, SRI and HADS, leading to significant differences between 
groups after 6 months. 
Both groups showed significant improvements on the attendant symptoms and sleep domain of 
the SRI which improved significantly in both groups. Within the non-ALS group, many 
domains improved significantly after both 2 and 6 months. By contrast, in the ALS group, only 
three domains of the SRI improved significantly after 2 and 6 months; only the attendant 
symptoms and sleep domain of the SRI was still significantly improved in the ALS group as 
compared to baseline. Two domains of the SRI, social functioning and social relationship, 
worsened significantly in the ALS group, showing also a significant difference between both 
groups. 
Discussion 
In this study, NIV was effective in improving gas exchange in both the ALS and the non-ALS 
group after 2 and 6 months. While NIV also clearly improved QOL in the non-ALS patients, 
the patients with ALS showed a different pattern. After 2 months, only three domains of the 
SRI questionnaire improved significantly. More importantly, quality of life became even worse 
in patients diagnosed with ALS as compared to the non-ALS group after 6 months of NIV.  
More than 150 patients start chronic ventilatory support every year at the Department of Home 
Mechanical Ventilation of our hospital. Patients visit the outpatient clinic before starting 
chronic ventilatory support. Until now, we advised ALS patients to start chronic ventilatory 
support mainly based on the premise of a longer maintained QOL or even improved QOL in 
the randomized controlled trial of Bourke [4]. While different assessments on different 
moments were used, our study showed that after 2 months of NIV, QOL was maintained above 
75 % of baseline in both groups. After 6 months, the domains physical functioning, role 
physical and role emotional of the SF-36 and physical functioning and social functioning of the 
SRI were under 75 % of baseline in the ALS group. Our group differs from that of Bourke et 
al., in that patients in the Bourke study had higher vital capacity and lower starting carbon 
dioxide at baseline compared to our study. In the Bourke study, there was a mean of 710 days 
after the first onset of weakness in any muscle before starting NIV. This suggests a similar 
moment of starting NIV in both studies, as the mean before the start of NIV in our study was 
686 days. Our limited results in ALS were not the result of a bulbar impairment as gas 
exchange improved, and more importantly, only 2 out of 30 patients had a bulbar problem. 
Most importantly, however, we have to take into account that we did not include a control 
group with ALS but no NIV in contrast to Bourke, and therefore, could not assess if the NIV 
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group was worse compared to a control group. There were also important other differences 
between the Bourke study and ours in the assessment of QOL. The SRI and the MRF-28 
questionnaires were specifically developed for patients with respiratory failure and, therefore, 
used in our study, next to the HADS and SF-36. It is remarkable to see that after  6 months of 
chronic ventilatory support in the ALS group, only the SRI domain attendant symptoms and 
sleep significantly improved. In contrast, the sum score of the SRI, MRF-28 and HADS 
improved significantly in the non-ALS group. We think that progression of the disease ALS is 
one of the reasons that most domains do not improve. 
Routinely, during a house call visit after a patient with ALS has died, we ask next of kin or 
caregivers to share their experiences with us. In general, we are told they are satisfied with the 
level of care and result of the therapy, comfort during sleep and more awake during daytime. 
However, during the last months of their life, these benefits disappear as leakage of the mask 
during ventilation becomes a burden for both the patient and relatives. The sound of air leaking 
by the mask and the ventilator wakes everybody, and does not provide any comfort anymore. 
We sometimes hear relatives make the remark that after the patient has died, it was a relief to 
see them lying in bed without mask and ventilatory support. These facts are worthwhile to 
consider and should be shared with patients before the start of HMV. 
A limitation of our study is that it was primarily set up as a randomized controlled trial, 
comparing initiation of NIV at home with an in-hospital start irrespective of diagnosis and, 
therefore, not to compare specifically ALS to non-ALS patients. Comparing patients with and 
without ALS is, from a life-expectancy perspective, imperfect and should be done with caution. 
To understand the results of the ALS group in a broader perspective, in a future study, patients 
with ALS should be randomized to receive NIV or not. However, starting a randomized 
controlled trial, one group with NIV and one group without, is probably, from an ethical 
perspective, not easy to realize, because NIV has become the cornerstone of symptom 
management in patients with ALS. 
Second, the ALS group had a smaller size than the non-ALS group resulting in lower chance of 
finding significant within group results compared to the non-ALS group. 
In conclusion, our study shows that NIV improves blood gasses in a wide range of patients, 
with or without ALS. However, in patients with ALS, QOL did not improve after 6 months of 
NIV relative to baseline, and some domains (social functioning, social relationship and 
physical functioning) even showed a significant deterioration compared to baseline. 
Given the doubt we create on the results of NIV in patients with ALS, we believe that 
prospective studies are warranted in ALS patients with proper randomized controlled setup for 
this question, using disease-specific QOL questionnaires. 
With regard to the other studies, we think that in our study, chronic ventilatory support was 
initiated in a more advanced stage of the disease. Therefore, we believe that these results raise 
questions about the efficacy of NIV in these specific patients, but they need to be confirmed in 
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a future dedicated randomized controlled trial in ALS patients using similar quality-of-life 
questionnaires. 
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Letter to the editor 
In the majority of studies, no Data and Safety Monitoring Board (DSMB) is either needed or 
instituted. We report an investigator initiated study where we should have done this earlier than 
we did and discuss the lessons we learned. 
The EOLUS study was a single center, randomized controlled trial of the initiation of chronic 
home mechanical ventilation (HMV) at home. Typical indications for HMV are neuromuscular 
diseases such as amyotrophic lateral sclerosis (ALS) and Duchenne's disease next to thoracic 
cage deformities. The study was set up to investigate whether the initiation of HMV at home 
with the help of telemonitoring was not inferior to our usual in hospital start. The primary 
outcome measure was change in arterial carbon dioxide pressure from baseline to 6 months, for 
which we calculated a necessary sample size of 52 evaluable patients. The study was 
performed by an experienced nurse practitioner, as part of a PhD project. Weekly informal 
supervision was done by a senior pulmonologist and monthly progress meetings were held in a 
larger group. At these meetings, inclusion, lists of those excluded, and dropouts with their 
reasons and all deaths were discussed and minutes were always made and distributed. At four 
occasions over the first 14 months, a death of a patient, all with ALS, was discussed. The 
number of deaths occurring in this severely ill patients group, nor the circumstances were 
deemed remarkable. After the inclusion of 33 patients, all events were totaled and presented as 
such. We were shocked to realize that all 4 patients had died in the home group and none in the 
hospital group. The study was immediately put on hold and we reported this to the medical 
ethics committee. The ethics committee requested detailed reports of all cases, and an 
independent view from experts not involved in the study, including a statistical analysis. The 
conclusion of the expert group was that the four patients had died due to the progression of 
their ALS, without an identifiable link to the intervention. They reported no lack of 
effectiveness in the survivors nor safety problems. The total number of deaths was deemed 
within the expected rates, but non-normally distributed. The ethics committee accepted the 
interpretation of the expert group, and decided to restart the study, with the requirement to 
institute a DSMB. All future severe adverse events were to be presented to the ethics 
committee immediately, as were the monthly progress reports of the DSMB. 
The study was subsequently finished as planned, with 77 patients randomized of which 30 with 
ALS. At the end, 5 patients in the home care and 2 patients in the hospital group had died, all 
with ALS. The hypothesis of non-inferiority of HMV institution at home with the help of 
telemonitoring was endorsed [1]. 
What did we learn? Most of all we came to fully realize that doing any study in patient groups 
with a high a priori risk of serious adverse events and especially of deaths, a DSMB with clear 
pre-set guidelines, meeting frequencies, minutes, and reporting lines to the ethics committee 
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should be in place. In our group, in investigator initiated studies, we had no rulings in place to 
see to the institution of a DSMB. We now firmly believe such a DSMB should be operational 
in all studies with high risk interventions. That is already frequently the case in long running 
pharmacy sponsored studies, and slightly less frequently in device company sponsored studies; 
investigator initiated studies are probably the biggest omission. 
The second lesson we learned is that we should have been keen on seeing at each meeting 
summary tables of all events having occurred. We did discuss all deaths, but became aware of 
the bigger, aggregate picture later than we should have. 
The DSMB consisted of a clinician expert in the field of chronic ventilation, a statistician and a 
clinical expert with expertise in clinical trials and methodology, all without any involvement in 
the conduct of the study. The DSMB evaluated the progress of the trial every four months and 
if necessary earlier depending on the monthly reports. 
In conclusion we believe that it is of great importance that a DSMB is involved in clinical trials 
not only with high risk interventions but also with high a priori risk of death due to disease 
under study. If the DSMB had been installed from the start of our study there would have been 
no reason to put the study on hold. Nevertheless, we learned greatly from the events and 
nowadays it is mandatory in our department that clinical trials with high risk of death by the 
intervention or the disease, must have an actively functioning DSMB. 
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Home mechanical ventilation is used for the treatment of chronic hypercapnic respiratory 
failure due to neuromuscular disease or thoracic cage disorder. In the majority of these patients 
there is an increased survival without any complications. However ventilatory support via a 
mask sometimes results in skin irritation, leakage and claustrophobia. In case of a 
tracheostomy, it can lead to increased pulmonary secretions and ulceration of the trachea. 
Diaphragm pacing might be an attractive alternative to prevent these complaints as it can 
prevent or replace the need for ventilatory support by mask or tracheostomy. Current 
indications are patients with spinal cord injury or with a congenital central hypoventilation 
syndrome. In our experience, patients can be completely or partially weaned from the 
mechanical ventilatory support when using a diaphragm pacer. In the Netherlands the 
technique is currently only performed in the University Medical Center Groningen. 




Diaphragm pacing system (DPS) is a technique in which the diaphragm is stimulated via the 






Four electrodes, two in the left and two in the right hemi-diaphragm, are implanted via a 
laparoscopic approach to the caudal side of the diaphragm (figure 2) and subsequently 
connected to the external pacemaker [1]. A fifth neutral electrode in the abdominal wall is also 
connected to the pacemaker. By stimulating the diaphragm with the external pacemaker the 





A: Implementation of the electrodes via a laparoscopic approach to the caudal side of the diaphragm 
 
 
B: Electrodes in the diaphragm 
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C: Contraction of the diaphragm after stimulation by the external pacer. 
 
After this inspiration, exhalation follows the moment that there is no stimulus. The frequency 
of the pacer, the duration and the intensity of the stimulus can be adjusted, resulting in a fully 
controlled inspiration. 
Why this new technology? 
In over 2200 patients, home mechanical ventilation is applied in the Netherlands at this time. In 
most patients this is without complications [2]. However there are several drawbacks during 
non-invasieve ventilation due to skin problems, problems finding a correct fit of the mask, or 
patients are experiencing claustrophobia. Problems may also occur during invasive ventilation, 
especially due to an increase in sputum induced by the tracheostomy tube. Regular change of 
the tracheostomy tube may lead to ulceration, and even bleeding of the surface of the trachea. 
There is a constant noise from the ventilator, patients have trouble talking and sometimes there 
is a reduced olfactory sensation. Finally, atrophy of the diaphragm will occur prolonged loss of 
activity, such as with mechanical ventilation. In addition, because of the complex and 
expensive care in patients with invasive ventilatory support, patients have difficulty in finding 
a place to live.  
The above mentioned problems indicate that alternatives are welcomed. DPS seems to be an 
attractive alternative because, depending on the underlying condition, it can replace the 




Patients with an indication for chronic ventilatory support due to missing or inadequate 
electrical stimulation of the diaphragm, such as spinal cord injury or congenital central 
hypoventilation syndrome may be eligible for DPS. The value in neuromuscular diseases with 
inadequate electrical conduction to the diaphragm, in particular in amyotrophic lateral sclerosis 
(ALS), is currently being investigated. DPS can only be effective if the conduction of the 
phrenic nerve to the diaphragm is intact from the place where it is stimulated. 
What problem does this solve? 
DPS is an alternative for patients who do not want to be dependent on a ventilator, mask or 
tracheostomy. This can be induced by skin problems and or leakage during use of a mask and 
the increase in sputum volume and the tendency to ulceration and bleeding in patients with 
invasive ventilatory support. 
What is known about the effectiveness? 
From March 2000 to September 2007, worldwide a diaphragm pacer was implanted in 88 
patients (50 spinal cord injury and 38 ALS) [4]. Complications as pneumothorax, infection and 
death did not occur during the laparoscopic surgery . Immediately following the procedure, 
transient abdominal pain did occur occasionally. During the period of training after the 
implantation, some patients experienced diaphragmatic fatigue or pain projected to the 
shoulder. After the pacer was set properly, 98% of patients with spinal cord injury used the 
pacer as respiratory support and 50% of patients used it 24 hours per day. ALS patients 
managed to postpone the start of chronic ventilatory support sometimes with more than one 
year.  
Within a pilot study conducted with the approval of the medical ethics committee, the 
University Medical Center Groningen (UMCG) included 4 patients with ALS. These four 
patients underwent the application of DPS without complications. The procedures went 
smoothly and was well accepted. Because all four patients subsequently started with non-
invasive ventilation, the standard therapy, it is difficult to state with certainty anything of the 
effects of the DPS. Currently, the effects of DPS in patients with ALS are studied in two 
randomized controlled trials in England and France. In two patients with spinal cord injury, 
DPS was implanted in the last year. The results of DPS in these two patients were very 
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positive. The first patient uses invasive ventilatory support at this time only during the night 
(this was 24 hours per day) and uses during the day DPS. In the other patient, the nocturnal 
non-invasive ventilatory support was totally replaced by DPS.  
How difficult is it to learn the technique? 
For the implantation of the electrodes in the diaphragm, experience with laparoscopic surgery 
is necessary. In the first two implantations in the UMCG, the procedure was performed by an 
abdominal surgeon (SH) in collaboration with an American surgeon (who had done more than 
100 implants). After this, the following four implantations were performed independently. 
After implantation, the patient follows a period of training to get used to the pacemaker 
gradually. Such counseling is done by a nurse from the department of home ventilation and is 
tailored to the specific situation of the patient in combination with the degree of dependency on 
ventilatory support.  
Expectations for the future? 
In America the Food and Drug Administration has approved DPS placement in patients with 
spinal cord injury and in patients with ALS. It is expected that the demand for DPS in the 
Netherlands will increase for patients with spinal cord injury because it provides an advantage 
over mechanical ventilatory support. Regarding the use of DPS in patients with ALS, we await 
the results of studies in England and France. Other indications are conceivable, for example 
double-sided diaphragm paralysis with intact conductance of the nervus phrenicus to the 
diaphragm, but these are still insufficiently investigated. 
Where in the Netherlands? 
In the UMCG, this specific technique is performed under guidance from the center of home 
ventilation (part of the department of pulmonary medicine and tuberculosis) in close 
cooperation with the abdominal surgery and anesthesiology departments. Because all patients 
who are eligible for DPS have chronic respiratory insufficiency and are treated by the 
departments of home mechanical ventilation it seems logical that these centers initiate and 
guide DPS. As long as the experience in the Netherlands is limited, it is wise to centralize DPS 





1. Onders RP, DiMarco AF, Ignagni AR, Mortimer JT. The learning curve for investigational 
surgery: lessons learned from laparoscopic diaphragm pacing for chronic ventilator 
dependence. Surg Endosc 2005; 19: 633-637. 
2. Hazenberg A, Cobben NA, Kampelmacher MJ, Rischen J, Wijkstra PJ. Home mechanical 
ventilation in the Netherlands. Ned Tijdschr Geneeskd 2012; 156: A3609. 
3. Onders RP, Elmo M, Khansarinia S, Bowman B, Yee J, Road J, Bass B, Dunkin B, 
Ingvarsson PE, Oddsdottir M. Complete worldwide operative experience in laparoscopic 
diaphragm pacing: results and differences in spinal cord injured patients and amyotrophic 
lateral sclerosis patients. Surg Endosc 2009; 23: 1433-1440. 
4. Onders RP, Khansarinia S, Weiser T, Chin C, Hungness E, Soper N, Dehoyos A, Cole T, 
Ducko C. Multicenter analysis of diaphragm pacing in tetraplegics with cardiac pacemakers: 
positive implications for ventilator weaning in intensive care units. Surgery 2010; 148: 893-7; 
discussion 897-8. 
 






The Lancet Neurology 2016; May 15 (6); 542-3 
 
Diaphragm pacing in patients with 
amyotrophic lateral sclerosis 
 
 
Peter J. Wijkstra 
Anda Hazenberg 




Diaphragm pacing in patients with amyotrophic lateral sclerosis 
101 
8 
Letter to the editor 
We read with great interest the report by the DiPALS Study Group Collaborators [1]. Their 
study showed that addition of diaphragm pacing to standard care during non-invasive 
ventilation was associated with decreased survival. The investigators concluded that diaphragm 
pacing should not be used as routine treatment for patients with amyotrophic lateral sclerosis in 
respiratory failure. 
In the study, patients with amyotrophic lateral sclerosis were included if they had respiratory 
insufficiency, as determined by decline of vital capacity, impaired sniff procedure, oxygen 
desaturation, or hypercapnia. The  latter is, by definition, a sign of hypoventilation, showing 
that non-invasive ventilation might be indicated. The ultimate goal of non-invasive ventilation 
is to improve gas-exchange. To establish whether non-invasive ventilation was effective in this 
trial, information about carbon dioxide, not only during daytime but also during the night, is 
needed. While saturation data are important, as suggested in the linked Comment on this 
Article [2], Christopher McDermott and co-authors did not provide any data on ventilation—ie, 
on carbon dioxide. The following data will help interpreting findings: baseline values of carbon 
dioxide and oxygen, and number of patients who were hypercapnic at baseline; carbon dioxide 
and oxygen during the night while on non-invasive ventilation and in patients allocated to 
diaphragm pacing; information on whether the diaphragm pacing system delivered adequate 
ventilatory support during the night; and data showing if ventilation was equally efficient in 
both groups of the trial. 
PJW has received a fee from Synapse Biomedical to give a lecture in 2013. All other authors 
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We present a case of facioscapulohumeral muscular dystrophy (FSHD) with a diaphragm 
paralysis as the primary cause of ventilatory failure. FSHD is an autosomal dominant inherited 
disorder with a restricted pattern of weakness. Although respiratory weakness is a relatively 
unknown in FSHD, it is not uncommon. 
Methods 
We report on the clinical findings of a 68-year old male who presented with severe dyspnoea 
while supine. 
Results 
Supplementing our clinical findings with laboratory, electrophysiological and radiological 
performances led to the diagnosis of diaphragm paralysis. Arterial blood gas in sitting position 
without supplemental oxygen showed a mild hypercapnia. His sleep improved after starting 
non-invasive ventilation and his daytime sleepiness disappeared. 
Discussion 
We conclude that in patients with FSHD who have symptoms of nocturnal hypoventilation, an 
adequate assessment of the diaphragm is recommended. This is of great importance as we 
know that nocturnal hypoventilation can be treated effectively by non-invasive ventilation.




Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant inherited disorder 
with a restricted pattern of weakness and is the third most common form of dystrophy [1]. In 
over 95% of the patients a deletion of a 3.3 kb tandem repeat, D4Z4, on chromosome 4q35 is 
present (FSHD type 1). In some cases (FSHD type 2), D4Z4 chromatin relaxation and stable 
double homeobox (DUX4) expression occur in the absence of D4Z4 array contraction [2]. 
FSHD type 1 and 2 are clinically characterized by asymmetric involvement of muscles in the 
facial, upper extremity, trunk and lower extremity region with variable severity (Table 1). 
 
Table 1. Ricci score, muscle strength was evaluated by using the Manual Muscle Testing Scale 
[3].  
0.5 Facial weakness 
1 Mild scapular involvement without limitation of arm abduction; no awareness of 
disease symptoms is possible 
1.5 Moderate involvement of scapular and arm muscles or both (arm abduction > 60° 
and strength ≥ 3 in arm muscles); no involvement of pelvic and leg muscles 
2 Severe scapular involvement (arm abduction < 60° on at least one side); strength < 
3 in at least one muscular district of the arms; no involvement of pelvic and leg 
muscles 
2.5 Tibioperoneal weakness; no weakness of pelvic and proximal leg muscles 
3 Mild weakness of pelvic and proximal leg muscles or both (strength ≥ 4 in all these 
muscles); able to stand up from a chair without support 
3.5 Moderate weakness of pelvic and proximal leg muscles or both (strength ≥ 3 in all 
these muscles); able to stand up from a chair with monolateral support 
4 Severe weakness of pelvic and proximal leg muscles or both (strength < 3 in at 
least one of these muscles); able to stand up from a chair with double support; able 
to walk unaided 
4.5 Unable to stand up from a chair; walking limited to several steps with support; may 
use wheelchair for most activities 




Although respiratory weakness is a relatively unknown feature of FSHD, it is not uncommon; 
one study reported that almost all of the patients will develop restrictive lung disease and 10–
20% will suffer from pulmonary complications (Table 2). 
 
Table 2. Main clinical findings [1]. 
Respiratory symptoms of hypoventilation Hypercapnia 
Dyspnoea while in supine position 
Fatigue 
Morning head age 
Neuromuscular symptoms Facial muscle weakness 
Shoulder girdle weakness 
Abdominal muscle weakness 
Lower-extremity muscle weakness 
Extramuscular symptoms High-frequency hearing loss 
Retinal telangiectasias 
Atrial arrhythmias  
Pain 
 
Patients with FSHD may become respiratory insufficient if they have progressive weakness of 
respiratory muscles and/or a scoliosis, most likely when there are other signs of functionally 
severe impairment such as the need to use a wheelchair [4]. In this case report we present a 
patient with FSHD who had a diaphragm paralysis as the primary cause of ventilatory failure. 
He was treated successfully with non-invasive positive pressure ventilation. 
Case report 
In 2008, at the age of 68, this man was diagnosed with Facioscapulohumeral muscular 
dystrophy (FSHD) type 1 (5 units 4A161). His medical history mentioned also psoriasis, high 
blood pressure for which he used bisoprolol, irbesartan, methotrexate and folate. He had also 
undergone surgery for penis carcinoma. His first complaints of muscle weakness were noticed 
at the age of 20 during a physical exam test. Exercise tolerance had been decreasing over the 
last 3–5 years. The last year he experienced severe dyspnoea when lying in supine position. He 
was referred to our hospital to evaluate his respiratory impairment. Normally he slept from 
11 PM till 7 AM, did not snore and because of breathlessness in supine position he preferred to 
sleep on his side with the top of the bed in uplift position. In the morning he woke up 
reasonably fit without a headache. During daytime he experienced fatigue and sleepiness, as do 
many FSHD patients [5,6], and he had to take a nap every afternoon. 
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The patient could still walk a short distance and up a flight of stairs, but this caused shortness 
of breath, and a mild tachypnoea. 
On physical examination, his weight was 97 kg, length 1.79 m, Body Mass index 29.7 kg/m
2
. 
He could not lift his arms above shoulder height. There was atrophy and muscle weakness of 
proximal as well as distal upper and lower extremities, back and abdominal muscles, but no 
signs of scoliosis. The Ricci score for clinical severity of FSHD was 3 [3]. Resting heart rate: 
70 beats/minute and resting respiratory rate 18 breaths/minute. In supine position there was 
paradoxical abdominal breathing and his respiratory rate increased. Arterial blood gas in sitting 
position without supplemental oxygen: acidity level (pH) 7.41, partial pressure of arterial 
carbon dioxide (paCO2) 6.1 kilopascal (kPa), partial pressure of oxygen (paO2) 9.7 kPa, 
bicarbonate (HCO3) 28.6 mmol/l, oxygen-saturation 95%. Nocturnal registration with the 
TOSCA
®
 transcutaneous monitor, before starting the chronic ventilatory support, showed a 
mean transcutaneous carbon dioxide (tcpCO2) of 7.8 kPa (4–6 kPa is normal) and a mean 
oxygen saturation (SpO2) of 91% (>92% is normal) [7]. The lowest saturation was 65% 
(Fig. 1). 
 
Figure 1.  
 
 
Nocturnal transcutaneous registration of carbon dioxide (mean 7.8 kPa) and oxygen saturation (mean 91%) before 
starting ventilation. 
 
To exclude that the patient had an obstructive sleep apnoea syndrome a polysomnography 
(PSG) was performed [5,8,9]. The PSG showed a disturbed sleep with short awakenings and an 
apnoea/hypopnoea index of 2/hour (<5 is normal). Pulmonary function tests showed a decline 
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in forced vital capacity (FVC) of 1.5 L when moving from sitting to supine position: FVC 
sitting 2.60 L (59% predicted), in supine position 1.10 L (25% predicted). Fluoroscopy of the 
diaphragm in supine position during a sniff maneuver revealed paradoxical diaphragm 
movement on both sides. 
Results 
To relieve his physical complaints and improve his alveolar hypoventilation he started non-
invasive positive pressure ventilation (NIPPV) during the night. The ventilator was set in the 
pressure assisted controlled mode with an inspiratory pressure of 24 cm H2O, a positive end 
expiratory pressure of 8 cm H2O and a frequency of 15 per minute. The patient used the 
ventilator every night with a mean usage of 7 h per night. His relationship with the ventilator 
was dual; he thought of it as an enemy because he had problems accepting the necessity to be 
ventilated, but also as a friend because it provided him better sleep and more energy during the 
day. While the vital capacity did not change after starting NIPPV, the arterial blood gas during 
the day at rest without ventilation did improve: pH 7.41, pCO2 5.9 kPa, pO2 11 kPa, HCO3 
28 mmol/l, oxygen-saturation 97%. Nocturnal registration one year after starting the NIPPV 





There is a relevant improvement in carbon dioxide (mean 6.1 kPa) and oxygen saturation levels (mean 94%) during 
ventilatory support. 




By using NIPPV the patient could now sleep in supine position. He slept better and he 
experienced more energy during daily activities. In addition he did not fall asleep anymore 
during daytime hours. 
Discussion 
This patient with FSHD had respiratory failure due to bilateral diaphragm paralysis as shown 
by the large drop in the vital capacity when changing from sitting to supine position in 
combination with paradoxical diaphragm movement during the sniff maneuver. A recent study 
concluded that the diaphragm should in principle not be paralyzed in patients with FSHD and 
therefore the authors did not recommend an evaluation of the diaphragm [10]. However, in that 
study patients were included who did not have symptoms of hypoventilation like morning 
headache, fatigue and daytime sleepiness, so it could be expected that the lung function was 
only mildly impaired. It is known that patients with FSHD can have complaints due to 
hypoventilation [4]. As an assessment of the vital capacity in both sitting and supine position 
and fluoroscopy of the diaphragm was not mentioned in that study, a paralysis of the 
diaphragm could have been missed as the primary cause of hypoventilation. Actual search and 
documentation of nocturnal hypoventilation is relevant since it can be treated effectively by 
NIPPV. We conclude that in patients with FSHD, who have symptoms of nocturnal 
hypoventilation such as morning headache, fatigue and daytime sleepiness, an adequate 
assessment of the diaphragm is recommended. 
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To the editors 
It was with great interest that we read the paper of Lo Mauro et al. [1] entitled “Abdominal 
volume contribution to tidal volume as an early indicator of respiratory impairment in 
Duchenne muscular dystrophy’’ in a recent issue of the European Respiratory Journal. This 
paper very elegantly explained the contribution of the abdominal volume to tidal volume if 
patients with Duchenne disease are getting older and change from sitting to supine position. 
Especially in figure 6 of that manuscript, one can see very clearly the different contribution of 
ribcage and abdomen (diaphragm) if the patient is getting older. Despite the important 
contribution of this paper in this field, we would like to make two comments. 
First, while the kinematic analysis was performed in both sitting and supine position, the 
pulmonary function tests were performed in sitting position only. This is a pity, as we know 
that a drop in vital capacity (VC), when a patient goes from sitting to supine position, is a sign 
of diaphragm paralysis. In contrast to optoelectronic plethysmography, spirometry in both 
positions is a simple test that can be performed in every hospital. Therefore, it would be 
interesting to know if the drop in the VC shows the same pattern in the different patients used 
in this study. For a physician taking care of these patients, it would be important to know 
whether he can rely on the VC in different positions to know whether the diaphragm is 
impaired or not. 
Secondly, in this paper the assessment of nocturnal hypoxaemia is presented as clinically 
relevant and seems to be more pronounced in the patients with a smaller change in abdominal 
volume. While this might be true, the point of nocturnal hypoventilation is missed in the 
discussion. It was shown in the paper by Ward et al. [2] that nocturnal hypoventilation, with 
normocapnia during daytime, is an important indicator of respiratory impairment. They showed 
that even in these patients chronic ventilation is of benefit and should be started at this 
moment. Therefore the paper could have been even more informative if data on nocturnal 
carbon dioxide were included. 
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The aim of this thesis was to innovate the field of home mechanical ventilation primarily to see 
whether chronic ventilatory support can be initiated effectively outside the hospital. Different 
tools were used during this study and the main findings are summarized below.  
 
Chapter 2 contains a review of home mechanical ventilation in the Netherlands over the last 2 
decades. The 4 centers of home mechanical ventilation in Rotterdam, Maastricht, Utrecht en 
Groningen collect data every year. Patients eligible for chronic ventilatory support are those 
with a neuromuscular disease, thoracic cage problem, sleep disordered breathing or chronic 
pulmonary obstructive disease. It is remarkable to see that patients with a neuromuscular 
disease are still the largest group in our country, being almost 70% of the entire group, which is 
in contrast with the other European countries. There is a considerable, 10% annual, increase in 
number of patients administered on ventilatory support. The growth is specifically seen in 
patients treated with the non-invasive form of ventilatory support. More than 80% of patients 
using chronic ventilatory support lives at home. The increase in complexity of care requires 
strict regulation to ensure safety and seems to be best guaranteed by centers providing home 
mechanical ventilation to a large group of patients. 
 
Chapter 3 shows the results of the validation of a transcutaneous carbon dioxide monitor 
compared with the golden standard, the arterial blood gas analysis, in adult patients with 
chronic respiratory failure. Paired measurements, arterial blood gasses and transcutaneous 
carbon dioxide, were taken in 15 patients. A maximum of 1.0 kilo Pascal difference was 
determined as clinically acceptable. Transcutaneous carbon dioxide measurement showed an 
acceptable agreement with the arterial blood gasses, during 8 hours of continuous 
measurement. Therefore, a transcutaneous monitor can be used to monitor carbon dioxide 
adequately during chronic ventilatory support. 
 
In chapter 4 the results of a randomized controlled trial in patients with an indication to start 
chronic ventilatory support are presented (EOLUS). Initiation of chronic ventilatory support is 
normally done in the hospital however this is expensive and often a burden to the patient. We 
investigated whether initiation of chronic ventilatory support at home in patients with chronic 
respiratory failure is non-inferior to the clinical setting. Seventy-seven patients were included, 
of which 38 started chronic ventilatory support at home.  All patients were diagnosed with 
chronic respiratory failure due to a neuromuscular or thoracic cage disease. Primary outcome 
was the arterial carbon dioxide, while quality of life and costs were secondary outcomes. 
Telemonitoring was used in the home group to provide therapeutic information to the health 
care professional. Arterial carbon dioxide improved significantly in both groups after 6 months 
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of follow-up, not being inferior in the home treatment group. Quality of life in the home group, 
from baseline to follow-up, was not inferior compared to the hospital group. Total mean costs 
per patient amounted to € 726 in the home group and € 3913 in the hospital group saving more 
than € 3000 during home initiation of chronic ventilatory support. From a patients’ perspective 
it is an ideal treatment as they do not have to be admitted to the hospital and their highly 
individualized care can be maintained during the initiation of chronic ventilatory support. 
  
Chapter 5 displays the results of a post hoc analysis of the EOLUS study detailed in chapter 4. 
Discussed is whether chronic ventilatory support is really effective in patients with 
amyotrophic lateral scleroses (ALS). Most patients with ALS develop complaints of dyspnoea, 
fatigue, unrefreshing sleep and morning headache in the advanced stage of their disease due to 
respiratory insufficiency. Chronic ventilatory support is commonly regarded to be a treatment 
that is effective in reducing these complaints. Several studies have presented data regarding the 
effects of chronic ventilatory support on quality of life in patients with ALS. Some were 
positive while others produced more limitations regarding starting chronic ventilatory support 
in these patients, most were not randomized controlled trials. Our analysis shows that chronic 
ventilatory support improved gas exchange in the ALS and the non-ALS group after 2 and 6 
months. While chronic ventilatory clearly improved quality of life in the non-ALS patients, the 
patients with ALS showed a different pattern. After 6 months of chronic ventilatory support, 
quality of life became worse in patients diagnosed with ALS compared to the non-ALS patients 
probably due to the progression of the disease ALS. However our results should be handled 
carefully as a control group of ALS patients not using ventilatory support was not included. 
 
In chapter 6 we discuss the installation of a data safety monitoring board (DSMB) in our non-
industry trial. The EOLUS study (chapter 4) started without a DSMB. After the inclusion of 33 
patients we noticed that 4 patients with ALS had died in the home treatment group 
(intervention) and none in the hospital group (control). The study was immediately put on hold 
and the medical ethics committee was informed. The ethics committee requested detailed 
reports of all cases, and an independent view from experts not involved in the study, including 
a statistician. Final conclusion of the expert group was that the 4 patients died due to the 
progression of their ALS, without an identifiable link to the intervention. If the DSMB had 
been installed from the start of the study there probably would have been no reason to put the 
study on hold. After this we realized that in this study involving patients with a high a priori 
risk of serious adverse events and especially of deaths an DSMB should have been installed at 
the start of the study. We believe this is relevant to all studies not only with high risk 
interventions, but also in patients with high risk of death irrespective of the intervention, as in 
our study. Such an DSMB is routinely installed in most industry driven studies, but perhaps not 
so in investigator initiated studies.  
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Chapter 7 describes an alternative for chronic ventilatory support; diaphragm pacing system 
(DPS). DPS is a technique in which the diaphragm is stimulated by an external pacemaker. By 
stimulating the diaphragm, the muscle contracts and moves down allowing air to be sucked 
into the lungs. After this inspiration, exhalation follows the moment that there is no stimulus. 
DPS might prevent the specific complaints associated with the use of chronic ventilatory 
support via a mask as skin irritation, leakage and claustrophobia and increased pulmonary 
secretion or ulceration of the trachea with a tracheostomy. Current indications are patients with 
spinal cord injury or a congenital central hypoventilation syndrome. In our experience, patients 
can be completely or partially weaned from the mechanical ventilatory support when using the 
diaphragm pacer. In the Netherlands the technique is currently only performed in the 
University Medical Center Groningen.  
 
In chapter 8 we responded to the DIPALS study, diaphragm pacing in patients with ALS. Our 
remark to the study is the lack of baseline data on carbon dioxide and oxygen. To be able to 
interpret the results of the study we would also like to see the effect of the treatment, chronic 
ventilatory support and diaphragm pacing, during the night. Assessment of carbon dioxide and 
oxygen in combination with the ventilator information can reveal whether the treatment is 
effective. 
 
Chapter 9 displays a case report of a 68 year old male with facioscapulohumeral muscular 
dystrophy (FSHD) and respiratory failure. FSHD is an autosomal dominant inherited disorder 
with a restricted pattern of weakness. In supine position, the patient experienced severe 
dyspnoea and he experienced daytime sleepiness. The polysomnography showed a disturbed 
sleep with short awakenings and an apneu/hypopneu index of 2 per hour (<5 is normal). 
Pulmonary function tests showed a decline in forced vital capacity (FVC) of 1.5 L when 
moving from sitting to supine position: FVC sitting 2.60 L (59% predicted), in supine position 
1.10 L (25% predicted). Arterial blood gas showed a mild hypercapnia. Fluoroscopy of the 
diaphragm in supine position revealed paradoxical diaphragm movement on both sides. The 
diaphragm paralysis was the cause of his respiratory failure. After the initiation of non- 
invasive chronic ventilatory support his gas exchange and sleep quality improved. We 
conclude that in patients with FSHD who have symptoms of nocturnal hypoventilation, an 
adequate assessment of the diaphragm is recommended. This is of great importance as we 
know that nocturnal hypoventilation can be treated effectively by non-invasive ventilation. 
  
In chapter 10 we point out that measuring pulmonary function in both sitting and supine 
position can be helpful as a diagnostic tool in patients with Duchenne muscular dystrophy. It 
could be a sign of diaphragm paralysis if vital capacity (VC) declines when a patient goes from 
sitting to supine position. Spirometry in both sitting and supine positions is a simple test that 
can be performed in every hospital. In addition, it is of importance to know if nocturnal 
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hypoventilation  is present while being normocapnic during the day as this is an important 
indicator of respiratory impairment. When in patients with Duchenne muscular dystrophy 
diaphragm paralysis or nocturnal hypoventilation is present, chronic ventilatory support should 
be considered. 
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General discussion and future perspectives 
The prevalence of patients on chronic ventilatory support is increasing due to more awareness 
for this treatment in combination with better technical options. To move forward in this fast 
growing group of patients with chronic ventilatory support, innovation is of importance to keep 
up with requests of patients and to reduce the burden to the health care system. In this chapter, 
all findings of the thesis will be integrated and discussed, with special focus on the implications 
for the clinical practice and their role in the upcoming  years. 
Chronic ventilatory support 
The primary goal of chronic ventilatory support is to improve quality of life by reducing the 
signs and symptoms of chronic hypoventilation. Earlier studies showed an improvement in 
blood gasses after the initiation of ventilatory support [1,2]. The results of our study showed 
the same result with regard to the improvement in blood gasses (chapter 4).  
During the inclusion period of the EOLUS study 380 patients started chronic ventilatory 
support of which 84 were eligible to participate. The largest group that was excluded consisted 
of 105 patients that were admitted to our or another hospital with an acute problem due to 
different diagnoses. Of the 29 patients with obesity hypoventilation syndrome only 2 
participated in the study. The other 27 patients had to start ventilatory support in the hospital 
immediately due to an episode of acute respiratory failure. If symptoms of obstructive sleep 
apnoea, hypoventilation, dyspnoea, daytime sleepiness, morning headache and generalized 
pitting edema are present in these patients, physicians should perhaps consider initiating 
chronic ventilatory support earlier [3,4].  
Another group of 14 patients, diagnosed with ALS, were presented at the emergency room with 
dyspnoea due to hypoventilation and or mucus problems. Subsequently these patients were 
admitted to start chronic ventilatory support immediately. These annotations indicate that for a 
sub group of patients the start of chronic ventilatory support in the hospital will probably 
remain necessary.  
The second large group that was excluded consisted of 90 patients with COPD, as non-invasive 
ventilatory support was still not common practice in this group of patients during our inclusion 
period. These patients participated either in a different clinical trial or started chronic 
ventilatory support in combination with rehabilitation [5]. Since the evidence for starting 
chronic ventilatory support also in these patients with COPD, it is logical to consider initiation 
of chronic ventilatory support at home as well in this group.  
In addition, the use of polysomnography and microchip cards with detailed ventilator 
information, can be of great importance in future studies to better evaluate the patient-
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ventilator interactions. From a clinical perspective this is an addition that could also have a 
downside especially as a patient experiences an improved quality of life while being on 
ventilatory support. Detailed information sometimes reveals periods of inadequate patient-
ventilator interaction without consequences for the effect of the treatment. So despite the fact 
that one is challenged to change settings of the machine, the best strategy in these patients 
could be “Never change a winning team”.  
The effect of chronic ventilatory support on quality of life in our study population was less 
positive compared to previous published studies [6-10]. Probably this is due to the large 
number of patients with amyotrophic lateral scleroses, which was over 35% (chapter 5). We 
performed a post hoc analysis in the patients who started chronic ventilatory support (chapter 
4). In this analysis we compared patients without ALS with those with ALS. At baseline, 
quality of life was higher in the non-ALS group than in the ALS group. Compared to the non-
ALS group, the ALS group had significantly less improvement after 6 months of chronic 
ventilatory support. Based upon the results of this analysis we concluded that chronic 
ventilatory support improves blood gasses in patients with or without ALS. However, in 
patients with ALS, quality of life did not improve after 6 months of chronic ventilatory support 
and some domains (social functioning, social relationship and physical functioning) even 
showed a significant decrease compared to baseline. These results, however, should be 
interpreted with great care as a control group without chronic ventilatory support was not 
included. Follow-up of our raised question in ALS should consist of a future study with only 
patients with ALS, randomized to chronic ventilatory support or usual care only. In such a 
study quality of life should be assessed by questionnaires suitable for patients with respiratory 
failure the SRI and the MRF-29.  
As described by Gonzalez there are two prognostic factors in patients with ALS which may 
indicate if chronic ventilatory support will be successful: the severity of bulbar involvement 
and the score of the ALSFRS-R questionnaire [11,12]. This means that we have to look at 
different phenotypes of ALS to select the right candidates for treatment with chronic 
ventilatory support. 
Telemonitoring 
To transfer health care from the hospital, we used telemonitoring to evaluate the initiation of 
chronic ventilatory support at home. Electronic data was collected from the mechanical 
ventilator and transcutaneous monitor, and with aid of a laptop and software specifically 
developed for this study, transferred to the hospital. There was a comparable improvement in 
blood gasses in both the home (intervention) and hospital (standard care) group, indicating that 
the initiation of chronic ventilatory support can be performed effectively and safely at home. 
Publications related to the initiation of chronic ventilatory support outside the hospital by using 
telemonitoring are scarce. Chapter 4 of this thesis displays a good example of the 
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implementation of telemonitoring. The results of the EOLUS study shows that the use of 
modern technologies in patients with a chronic disease can lower the burden to the health care 
system as admitting them to the hospital is no longer necessary. We want to stress that the 
initiation of chronic ventilatory support was continued even if data was not sent to the hospital 
due to technical problems such as bad connection to the mobile network. In those cases a 
telephone call or house visit was done.  
Another remarkable outcome of our results was that in the hospital group the nurse had double 
contact time with the patient compared to the home group. A reason could be that in the 
hospital it is tempting to visit a patient again if you are present on the ward. Another reason is 
that in the hospital often something else draws your attention, the emergency room, the 
outpatient clinic or a meeting with other team members which disturbs the moment you are 
sharing information with the patient making it less effective. At home this is quite the opposite 
resulting in optimal time investment for both the patient and the nurse. The visits at home took 
more time per visit but were less frequent than in the hospital. Future studies have to focus on 
which type of patient is a good candidate for home initiation.   
A problem is the lack of regulation on what exactly is meant by telemonitoring, telemedicine 
and telehealth. Searching the internet reveals many hits but not a final conclusion of which 
term to use in what circumstances. Further improvements in both technical and digital 
possibilities in the upcoming years will facilitate the development of future e-health studies. 
One initiative is the HOMERUN study, a Dutch multi-center randomized controlled trial, 
which started May 2015. The HOMERUN study explores the national implementation of the 
initiation of chronic ventilatory support outside the hospital. Our aim is that in 2020 Dutch 
patients who are eligible for initiation of chronic ventilatory support at home can start it at 
home. Both health care professionals and manufactures of ventilators and transcutaneous 
monitors are challenged to explore all new technical and digital possibilities in order to 
facilitate initiation of chronic ventilatory support at home.   
Transcutaneous monitoring of carbon dioxide 
To initiate chronic ventilatory support outside the hospital we needed an alternative for 
measuring carbon dioxide in arterial blood (the golden standard). Therefore we performed a 
validation study of the TOSCA
®
 transcutaneous monitor and concluded that there was an 
acceptable agreement with arterial blood gasses both on carbon dioxide and oxygen saturation. 
This means that the transcutaneous monitor can be used at home to assess gas exchange while 
being ventilated.  
In contrast to arterial blood gasses, which is a single measurement, the TOSCA
®
 measures 
continuously gas exchange while a patient uses the ventilator and therefore provides more 
information. By using both transcutaneous assessment and ventilator information one can 
monitor the ventilatory support minute by minute which is not possible with arterial blood 
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gasses. When in the hospital in this study, we used radial arterial lines to be able to repeat 
arterial blood gasses, which has the disadvantage of patients waking up or being aroused while 
a sample is taken, influencing the result. In our setting, to make it worse, the arterial lines were 
employed only at the intensive care unit making sleep even more challenging.    
A recently published article concluded that transcutaneous measuring of carbon dioxide is 
accurate and can replace arterial samples to evaluate the effect of the chronic ventilatory 
support [13]. However another study showed that in patients with severe hypercapnia the 
difference between arterial and transcutaneous carbon dioxide increases, suggesting that its 
accuracy depends on the level of hypercapnia [14]. In both studies there are no remarks about 
the assessment in case of low levels of carbon dioxide. It would be interesting to explore this in 
a group of patients especially those with a neuromuscular disease, as we often see that they 
appreciate a low carbon dioxide level to feel comfortable. 
Diaphragm paralysis 
While unilateral diaphragm paralysis is often asymptomatic and is revealed by coincidence, a 
bilateral diaphragm paralysis is a more serious and sometimes life threatening condition. 
Paralysis of the diaphragm may result in dyspnoea or orthopnoea. There are different 
diagnostic tools to confirm that paralysis of the diaphragm is present. First, the physical exam 
of a patient in supine position shows paradoxical movement of the abdomen during inspiration. 
Diaphragm elevation can be diagnosed by chest X-ray but not its movement. Thirdly, the 
assessment of spirometry in both sitting and supine position can be helpfull. In supine position 
vital capacity shows a larger drop compared to sitting position. The sniff-test during 
fluoroscopy, showing no  (or even paradoxical) movement of the diaphragm in supine position, 
should complete the diagnostic process. Some centers use ultrasound for the latter 
determination. 
There are 3 therapeutic options in case of diaphragm paralysis:  
 non-invasive ventilatory support 
 plication of the diaphragm 
 diaphragm pacing.  
Ventilatory support can solve the problem of dyspnoea and orthopnea during the night while 
asleep in supine position as described in chapter 8. However, patients still complain about 
dyspnoea on exertion and orthopnoea while swimming or when kneeling down interfering with 
daily activities. In these cases plication of the diaphragm might me more effective, as it 
prevents paradoxical movement on inspiration. A recent study showed that tidal volume 
increases in combination with a decrease in ventilatory frequency after plication [15]. Despite 
this improvement exercise capacity remained unchanged.  
Ventilatory support and plication are optional treatments in both unilateral and bilateral 
diaphragm paralysis.  
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Diaphragm pacing is currently only applicable in bilateral diaphragm paralysis and only 
effective if the phrenic nerve can be stimulated close to the diaphragm. Patients with an 
indication for chronic ventilatory support, such as spinal cord injury or congenital central 
hypoventilation syndrome may be eligible for diaphragm pacing. The value in neuromuscular 
diseases in particular in amyotrophic lateral sclerosis was also recently investigated. A 
randomize controlled trial was terminated, as an interim-analysis showed that patients who 
used the pacer died earlier compared to patients who did not used it [16]. The main conclusion 
of the DiPALS group was that diaphragm pacing should not be used as standard care in 
patients with ALS because it was associated with decreased survival. In our hospital we 
implanted the diaphragm pacer also in patients with ALS at the start of the introduction of this 
technique (chapter 7). The last years we only implanted the pacer in patients with a SCI. Some 
cases offered great short term results but others with were disappointing, depending on the 
clinical situation and mental condition of the patient.  
Chronic ventilatory support, plication or pacing are all therapeutic ways to solve the patients 
problems. “Which is best” should be the question to be answered in future studies. Three 
hospitals in the Netherlands combined their experiences in treating these patients and are 
setting up a study to follow-up the different approaches and their outcome. The coming years 
we want to investigate the benefits of the different treatments in patients with an unilateral 
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De longen zorgen ervoor dat tijdens de inademing zuurstof in het lichaam komt en dat bij de 
uitademing koolzuurgas wordt uitgeademd. De belangrijkste spieren die daarbij actief zijn, zijn 
het middenrif en je hulpademhalingsspieren. Ademhalen doe je zonder erbij na te denken en 
wordt geregeld vanuit het ademhalingscentrum gelegen in de hersenen. Een effectieve 
ademhaling en gaswisseling is afhankelijk van een goede werking van het 
ademhalingscentrum, de longen, de ademhalingsspieren en een goede bewegelijkheid van de 
borstkas.  
Chronische beademing in Nederland 
Een patiënt die chronisch beademd wordt, is buiten het ziekenhuis afhankelijk van een 
beademingsapparaat om de ademhaling te ondersteunen, meestal voor de rest van het leven. 
Beademing wil zeggen dat de ademhaling wordt overgenomen door een beademingsapparaat. 
In Nederland wordt chronische beademing in de thuissituatie sinds 1960 toegepast, nadat door 
de poliomyelitis epidemie in de jaren 50 een grote groep patiënten langdurig afhankelijk was 
van een beademingsapparaat. De afgelopen jaren is het aantal patiënten met chronische 
beademing fors toegenomen tot bijna 3000 in 2016.  
 





Chronische beademing lukt steeds beter via een beademingsmasker (figuur 1) waardoor het 
aantal patiënten dat een canule (opening via de huid in de hals naar de luchtpijp, figuur 2) 
nodig heeft de laatste 10 jaar is gedaald van 40% naar 19% van de totale groep met chronische 
beademing.  
 
Figuur 2. Tracheostoma. 
 
Patiënten die in aanmerking komen voor chronische beademing zijn onder te verdelen in 4 
groepen (tabel 1). 
De eerste groep omvat patiënten met een zenuw- en/of spierziekte. Voorbeelden zijn patiënten 
met spierzwakte (bijvoorbeeld ziekte van Duchenne), amyotrofische laterale sclerose (ALS), 
een dwarslaesie of een verlamming van het middenrif.  
De tweede groep wordt gevormd door patiënten met een borstkasafwijking, bijvoorbeeld een 
aangeboren scheve of kromme rug. De mensen met een ademhalingsprobleem ten gevolge van 
overgewicht worden ook tot deze groep gerekend omdat de dikke buik het bewegen van de 
borstkas beperkt.  
De derde groep betreft patiënten met een longziekte. In Nederland krijgen worden op dit 
moment patiënten met een longemfyseem (COPD) meer en meer een indicatie voor chronische 
beademing maar doen ook nog veel mee aan wetenschappelijk onderzoek waardoor zij ook 
beademing krijgen. Patiënten die op de wachtlijst staan voor een longtransplantatie, 
bijvoorbeeld patiënten met taai slijm ziekte, kunnen in aanmerking komen voor chronische 
beademing als overbrugging naar transplantatie.  
De vierde groep betreft patiënten met een slaap gerelateerde ademhalingsstoornis zoals het 









Het belangrijkste bij chronische beademing is het verbeteren van de kwaliteit van leven door 
het verminderen van de klachten die vaak een gevolg zijn van hypoventilatie (te weinig 
ademen). Hypoventilatie, door spierzwakte of beperkte beweging van de borstkas, kan een 
aantal klachten veroorzaken als vermoeidheid, hoofdpijn bij het wakker worden, nachtmerries, 
spontane benauwdheid tijdens de nacht, concentratiestoornissen, sufheid en verminderde 
eetlust.  
Tijdens het instellen van een patiënt op chronische beademing is het belangrijk dat wordt 
geprobeerd om het koolzuur- en zuurstofgehalte te verbeteren. Diverse onderzoeken hebben 
aangetoond dat de kwaliteit van leven verbetert na het starten met chronische beademing. Ook 
het sociaal en geestelijk functioneren verbetert en tegelijkertijd ook de vitaliteit, het denken en 
het uithoudingsvermogen. Chronische beademing heeft daarnaast een duidelijk positieve 
invloed op de overleving, 70% van de patiënten met de ziekte van Duchenne waren na 5 jaar 
nog in leven. Van de patiënten met een postpoliosyndroom was 10 jaar na het starten met 
chronische beademing 70% nog in leven. Door de afname van het aantal ziekenhuisopnames en 
de verbeterde conditie is deze behandeling ook kostenbesparend.  
In Nederland wordt als regel het instellen van chronische beademing in het ziekenhuis gedaan, 
in een opname van bijvoorbeeld 8 dagen op een gewonde afdeling, en zelfs 2 nachten op een 

























instellen op chronische beademing ook buiten het ziekenhuis kan. Hiervoor zijn verschillende 
technieken gebruikt. De belangrijkste conclusies zijn beschreven in de volgende hoofdstukken. 
 
Hoofdstuk 2 geeft een overzicht van de chronische beademing over de afgelopen 20 jaar. Er 
zijn in Nederland 4 centra voor thuisbeademing en die bevinden zich in Rotterdam, Maastricht, 
Utrecht en Groningen. De patiënten met een zenuw- en spierziekte zijn de grootste groep, bijna 
70%. Het aantal patiënten met chronische beademing groeit elk jaar met 10%. Meer dan 80% 
van de patiënten met thuisbeademing verblijft thuis. Het instellen op chronische beademing is 
maatwerk. Het gebruik van de juiste beademingsapparatuur en van het juiste 
beademingsmasker of canule vraagt tijd en aandacht en is belangrijk voor een goed resultaat. 
De centra voor thuisbeademing kunnen door hun jarenlange ervaring op dit gebied de patiënten 
met de beschikbare middelen professioneel begeleiden in het ziekenhuis en de thuissituatie. De 
centra voor thuisbeademing bemerken de laatste jaren een toename van patiënten die 
complexere zorg nodig hebben. Omdat bij complexere patiënten er vaak weinig tijd per dag 
zonder beademing is moeten strikte voorwaarden zorgen voor een veilige situatie.  
 
In hoofdstuk 3 is beschreven hoe het meten van het koolzuur en zuurstof gehalte buiten het 
ziekenhuis kan. We hebben de gouden standaard, bloed uit de polsslagader, vergeleken met een 
meting via de huid met behulp van een sensor op de oorlel (transcutaan). De conclusie was dat 
de waarden van het koolzuur- en zuurstofgehalte bijna hetzelfde zijn als die in het bloed. Deze 
meting kan dus goed worden gebruikt voor het meten buiten het ziekenhuis.  
 
Hoofdstuk 4 laat de gegevens zien van een onderzoek (EOLUS) bij 77 patiënten die moesten 
worden ingesteld op chronische ademhalingsondersteuning. Deze patiënten hadden een zenuw- 
of spierziekte of een vergroeiing van de borstkas. Loting bepaalde dat 38 patiënten thuis zijn 
ingesteld op de beademing en dat 39 patiënten moesten worden opgenomen in het ziekenhuis. 
Buiten het ziekenhuis maakten we gebruik van telemonitoring, het op afstand bekijken van 
gegevens van het beademingsapparaat en van de meet apparatuur. Zes maanden na het instellen 
op de beademing werden de gegevens van beide groepen met elkaar vergeleken. Het koolzuur- 
en zuurstofgehalte en de kwaliteit van leven verbeterde in beide groepen vergelijkbaar, 
waarmee is aangetoond dat het instellen op beademing in de thuissituatie niet alleen veilig 
maar ook even effectief was. Daarbij is het instellen op de beademing thuis veel goedkoper, het 
scheelt namelijk €3000,- per patiënt. En belangrijk, het is voor de patiënt, die thuis vaak alles 
heeft ingericht om zo goed mogelijk te kunnen wonen, prettig dat die niet hoeft te worden 
opgenomen in het ziekenhuis.  
 
In hoofdstuk 5 hebben we de gegevens van het EOLUS onderzoek dat is beschreven in 
hoofdstuk 4 nader onderzocht. Het aantal patiënten dat heeft deelgenomen aan het onderzoek 




meeste patiënten met ALS krijgen last van benauwdheid, vermoeidheid, worden niet 
uitgeslapen wakker, dromen eng en hebben soms hoofdpijn als de ademhalingsspieren niet 
meer goed werken. Beademing helpt bij het voorkomen van deze klachten en wordt wereldwijd 
gezien als een effectieve therapie. Na het opsplitsen van de totale groep in een ALS en niet 
ALS groep zagen we dat het koolzuur- en zuurstofgehalte verbeterde na 6 maanden in beide 
groepen. Met betrekking tot de kwaliteit van leven zagen we echter dat de ALS groep 
verschilde van de niet ALS groep. De ALS groep was nog wel na 2 maanden verbeterd maar 
niet na 6 maanden chronische beademing en dit kan heel goed komen door de snelle 
verslechtering van de situatie door de ziekte ALS. Het ontbreken van een controle groep 
(patiënten met ALS die niet beademd worden) betekent echter dat echte harde conclusies hier 
niet aan verbonden kunnen worden. Maar de resultaten rechtvaardigen het uitvoeren van een 
goed gecontroleerde studie.  
Tijdens het EOLUS onderzoek zijn ook patiënten overleden. Op een gegeven moment werd het 
duidelijk dat in de groep die thuis werd ingesteld 4 patiënten waren overleden en nog geen 
enkele in de ziekenhuisgroep. Het onderzoek is toen gelijk stop gezet en er is een melding 
gedaan bij de medische ethische commissie van het ziekenhuis. In samenspraak is onder andere 
een DSMB (data safety monitoring board = gegevens en veiligheid bewakingsgroep) ingesteld 
om naar de resultaten tot dan toe te kijken. Na het bekijken van alle rapporten is gelukkig 
geconcludeerd dat het overlijden niet aan het thuis instellen lag maar aan de snelle 
verslechtering van de ziekte van de betrokken patiënten en mocht het onderzoek verder worden 
afgerond.  
 
De DSMB met daarin 2 artsen en een deskundige op het gebeid van statistiek, die allemaal niet 
betrokken waren bij het EOLUS onderzoek, controleerde vanaf dat moment alle gegevens van 
het onderzoek en dat is beschreven in hoofdstuk 6. Aan het eind van de studie waren 5 
patiënten overleden in de thuisgroep en 2 in de ziekenhuisgroep, hetgeen meer in balans is. De 
les die we hieruit geleerd hebben is dat het installeren van een DSMB altijd moet, niet alleen 
als de ingreep van de studie wellicht risicovol is (dat viel hier wel mee), maar ook als de 
patiënten die deelnemen een hoge vooraf kans hebben om te overlijden, los van de studie. 
 
Een alternatief voor chronische beademing is beschreven in hoofdstuk 7. Diafragma 
(middenrif) pacing wordt gedaan met een pacemaker buiten het lichaam. Door middel van een 
kijkoperatie in de buik worden 4 elektroden op het middenrif bevestigd. Door het aanzetten van 
de pacemaker trekt het middenrif samen en wordt er lucht naar binnen gezogen. Als de 
pacemaker stopt ontspant het middenrif en ademt de patiënt weer uit. Patiënten met een hoge 
dwarslaesie die in aanmerking komen voor chronische beademing kunnen geschikt zijn voor 
middenrifpacing. Middenrifpacing kan een alternatief zijn voor patiënten die niet afhankelijk 
willen zijn van een beademingsapparaat met beademingsmasker of tracheacanule. Redenen 
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hiervoor zijn onder andere een geïrriteerde huid bij gebruik van een beademingsmasker of 
meer slijmproductie bij gebruik van een canule. 
 
In hoofdstuk 8 geven we een reactie op een onderzoek dat is gepubliceerd over 
diafragmapacing bij patiënten met ALS.  Om de resultaten van dat onderzoek goed te kunnen 
bekijken hebben we gegevens nodig van het koolzuur- en zuurstofgehalte, overdag gemeten, en 
die zijn niet beschreven. Het gaat dan om de gegevens voor dat met de beademing is begonnen. 
Ook het effect van de beademing of de diafragmapacing tijdens de nacht is niet beschreven aan 
de hand van het koolzuur- en zuurstofgehalte aangevuld met de gegevens van het 
beademingsapparaat. Dit maakt het lastig is om de resultaten van het onderzoek te beoordelen. 
 
In hoofdstuk 9 en 10 wordt beschreven dat een middenrif verlamming ook kan voorkomen bij 
patiënten met een zenuw of spierziekte. Dit kan dan de reden zijn om chronische beademing te 
starten terwijl dan de klachten van te weinig ademen door de zenuw- of spierziekte nog niet 
aanwezig zijn. Door middel van een blaastest in zittende en liggende positie is vast te stellen of 
er een probleem aanwezig is. Bij een verlamming van het middenrif kan een patiënt in liggende 
positie niet zoveel lucht verplaatsen en dat is dan te zien in de uitslag van de blaastest. Na het 
starten met chronische beademing bij patiënten met een middenrif verlamming, verbetert de 





















Aan het eind van van mijn promotietraject denk ik: hoe is het toch zo gekomen, van 
verpleegkundig specialist naar promovenda? Het begint met een idee en vervolgens word je 
gevraagd om te promoveren. Terugkijkend heb ik geen spijt van mijn beslissing om ja te 
zeggen. Ik heb de afgelopen jaren veel geleerd en ook genoten van alle bijzondere momenten 
en ervaringen. Het was niet altijd eenvoudig om te voldoen aan de eisen, maar het is gelukt en 
dat geeft veel voldoening. Het doet mij ook goed dat er een vervolg is op mijn onderzoek, de 
landelijke implementatie onder de naam HOMERUN. Het blijft niet in een la liggen. Dit alles 
was niet gelukt zonder de hulp van velen en die wil ik daarvoor bedanken. Mocht je hierna niet 
met naam worden genoemd, mijn dank is daardoor niet minder groot. 
 
Allereerst wil ik alle deelnemers aan het EOLUS onderzoek bedanken. Door jullie deelname 
hebben we kunnen bewijzen dat het instellen op de beademing ook heel goed in de thuissituatie 
kan. De inzet van u als patiënt en alle hulpverleners maakte het mogelijk en heb ik als 
waardevol ervaren. 
 
Promotor Prof. Dr. P.J. Wijkstra, beste Peter. Tja, waar zal ik beginnen? Je was eerst de 
copromotor, maar werd mijn promotor. Dat was een bijzonder moment voor ons allebei. Ook 
bijzonder was het vertrouwen dat je had in mijn kunnen. Terwijl ik achter het stuur zat van de 
Volvo, op weg naar een overleg met TNO, deed jij uit de doeken waarom jij dacht dat ik zou 
kunnen promoveren. In de loop van de jaren heb je me steeds vertrouwen gegeven, gezorgd dat 
ik de moed er in hield en zag je steeds het licht aan de horizon. Samen hebben we het een en 
ander bereikt zoals het binnenhalen van de ZonMw subsidie voor de landelijke HOMERUN 
studie en dat voelt goed. Heel erg bedankt voor alles. 
 
Promotor Prof. Dr. H.A.M. Kerstjens, beste Huib, ook jij bent een van die bijzondere 
‘ervaringen’ tijdens mijn promotie traject. De eerste overleggen dacht ik vaak: waar heeft die 
man het over, hoe ga ik dit ooit volgen? Dat lukte steeds beter en uiteindelijk heb ik geleerd 
steeds verder vooruit te denken en te anticiperen op wat me te wachten stond. Het leren tijdens 
het promoveren stond bij jou voorop en ik heb zeker veel van je geleerd. Ik voelde me wel af 
en toe wat te kort schieten, maar dat heb je nooit laten merken. Er werd dan een extra overleg 
gepland en dan kon ik weer verder. Ook kon je goed omgaan met een kritische noot van mijn 
kant en dat maakte het contact prettig. Heel erg bedankt voor de afgelopen jaren. 
 
Het team van het Centrum voor Thuisbeademing, zonder jullie was het niet gelukt. Aaf, 
Anneke en Chiel, jullie werken niet meer bij de thuisbeademing, maar waren wel betrokken bij 
de opstart van het onderzoek. Nog bedankt voor jullie bijdrage. Jellie bedankt voor het 
rekruteren van de deelnemers voor het onderzoek. Altijd kon ik bij jou terecht met vragen. De 
overige collega’s bedankt voor jullie inzet en mocht er iemand zijn die ook wil promoveren 




Dr. F.M. Verdonk-Struik, Fransien, jij bent al een tijdje klaar met je promotie en gesetteld in 
Zeist. Toch hebben we nog regelmatig contact en dat is altijd gezellig en waardevol. Toen we 
nog samen op één kamer zaten hadden we veel aan elkaar en hadden we elke dag een moment 
van overleg met de benen op tafel. We konden ook uren aan een stuk werken zonder te praten. 
Als dan op de radio onze favoriete quiz werd uitgezonden deden we beide onze oortjes in en 
probeerden mee te doen. De quiz eindigde altijd met: “Ladies and gentlemen, we have got 
ourselves a winner!”. Een winnaar ben jij al een tijdje en ik nu bijna ook. 
 
De leescommissie, bestaande uit prof. dr. J.E. Tulleken, prof. dr Y. Heijdra en prof. dr. D. 
Gommers, wil ik bedanken voor hun bereidheid tot het lezen en beoordelen van mijn 
proefschrift.  
 
Ik wil alle co-auteurs bedanken voor hun bijdrage aan de manuscripten; dr. K.M. Vermeulen, 
ir. S.C.L. Prins, dr. N.A. Cobben, drs. J. Rischen, dr. N.B.M. Voet, drs. J.A. Nieuwenhuis, dr. 
N van Alfen, J.G. van der Aa, drs. H.S. Hofker, dr. M.J. Kampelmacher en prof. dr J.G. 
Zijlstra. 
 
Tijdens mijn promotietraject zat ik in de onderzoeksgroep van de longziekten. Ook al was ik 
niet altijd aanwezig toch had ik het gevoel erbij te horen en te delen in de moeilijke en 
plezierige momenten. Zo was ik op een bruiloft, ging ik op kraamvisite en hoorde de perikelen 
rond het afrijden voor het rijbewijs. Ook kon ik er altijd terecht met vragen. Bedankt allemaal 
en we hebben het toch maar gefikst. 
 
Collega’s van de GRIAC bedankt voor de fijne samenwerking. Het was altijd inspirerend om 
mee te doen met de wekelijkse bijeenkomsten. 
 
Vivisol Nederland, ResMed, Zorgverzekeraars Nederland (Menzis) en het innovatiefonds van 
het UMCG hebben dit onderzoek financieel ondersteund. Daarvoor hartelijk dank. 
 
Lyanne en Sylvia, mijn paranimfen. Lyanne ken ik al mijn hele leven, ze is mijn zus. Ze werkt 
als verpleegkundig specialist in het Justitieel Complex Zaandam. Onze werkvelden liggen ver 
uit elkaar, toch hebben we raakvlakken. We kunnen daar altijd goed over praten en het levert 
altijd wat op. Sylvia is mijn nichtje. We startten tegelijkertijd met onze studie, zij als student 
geneeskunde en ik als verpleegkundig specialist, dat maakt onder andere onze band speciaal. 
Zij is nu huisarts en moeder. 
 
Tenslotte wil ik mijn familie en vrienden bedanken voor de steun in de afgelopen jaren. Het 




Toch hebben jullie altijd belangstelling getoond en zie ik het helemaal zitten om het met jullie 
te gaan vieren. Mijn vader en schoonvader zijn er niet bij maar zeker nog aanwezig. Mijn vader 
had als motto, ga de wereld in en maak er wat van. Wat zou hij er graag bij zijn geweest. 
Mama, mooi dat jij er bij kan zijn. Leo en Conny bedankt voor jullie steun de afgelopen jaren. 
Ignez, Erwin en Connie, fijn dat jullie er zijn. Moeder Nijboer, altijd in voor visite en een 
luisterend oor. Ria bedankt voor je belangstelling en steun en dat je alle contacten onderling zo 
goed weet te behouden. Pieter altijd rustig aanwezig. Tobias, Jayden en Joya bedankt voor de 
vrolijke noot in de afgelopen jaren. 
 
Jans, een rustpunt in mijn bestaan, je hebt me altijd gesteund met wijze raad. Ook weet je net 
op het moment dat het moet me uit te dagen om weer een stap extra te doen. Ik ben heel blij dat 
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